<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>First‐line drugs for hypertension - Wright, JM - 2018 | Cochrane Library</title> <meta content="First‐line drugs for hypertension - Wright, JM - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001841.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="First‐line drugs for hypertension - Wright, JM - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001841.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001841.pub3" name="dc.identifier" scheme="DOI"/> <meta content="First‐line drugs for hypertension" name="citation_title"/> <meta content="James M Wright" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="jim.wright@ti.ubc.ca" name="citation_author_email"/> <meta content="Vijaya M Musini" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Rupam Gill" name="citation_author"/> <meta content="Manipal University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD001841.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/04/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001841.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001841.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001841.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐Antagonists [therapeutic use]; Angiotensin‐Converting Enzyme Inhibitors [therapeutic use]; Antihypertensive Agents [adverse effects, *therapeutic use]; Calcium Channel Blockers [therapeutic use]; Coronary Disease [prevention &amp; control]; Hypertension [*drug therapy, mortality]; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors [therapeutic use]; Stroke [prevention &amp; control]; Thiazides [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001841.pub3&amp;doi=10.1002/14651858.CD001841.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001841\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001841\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","pt","ms","ja","hr","pl","fr","th","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001841.pub3",title:"First\\u2010line drugs for hypertension",firstPublishedDate:"Apr 18, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001841.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001841.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001841.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001841.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001841.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001841.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001841.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001841.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001841.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001841.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>50917 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001841.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/appendices#CD001841-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/table_n/CD001841StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/table_n/CD001841StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">First‐line drugs for hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#CD001841-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>James M Wright</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#CD001841-cr-0003">Vijaya M Musini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information#CD001841-cr-0004">Rupam Gill</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information/en#CD001841-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 April 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001841.pub3">https://doi.org/10.1002/14651858.CD001841.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001841-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001841-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001841-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001841-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001841-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001841-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001841-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001841-abs-0001" lang="en"> <section id="CD001841-sec-0001"> <h3 class="title" id="CD001841-sec-0001">Background</h3> <p>This is the first update of a review published in 2009. Sustained moderate to severe elevations in resting blood pressure leads to a critically important clinical question: What class of drug to use first‐line? This review attempted to answer that question. </p> </section> <section id="CD001841-sec-0002"> <h3 class="title" id="CD001841-sec-0002">Objectives</h3> <p>To quantify the mortality and morbidity effects from different first‐line antihypertensive drug classes: thiazides (low‐dose and high‐dose), beta‐blockers, calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers (ARB), and alpha‐blockers, compared to placebo or no treatment. </p> <p>Secondary objectives: when different antihypertensive drug classes are used as the first‐line drug, to quantify the blood pressure lowering effect and the rate of withdrawal due to adverse drug effects, compared to placebo or no treatment. </p> </section> <section id="CD001841-sec-0003"> <h3 class="title" id="CD001841-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to November 2017: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We contacted authors of relevant papers regarding further published and unpublished work. </p> </section> <section id="CD001841-sec-0004"> <h3 class="title" id="CD001841-sec-0004">Selection criteria</h3> <p>Randomized trials (RCT) of at least one year duration, comparing one of six major drug classes with a placebo or no treatment, in adult patients with blood pressure over 140/90 mmHg at baseline. The majority (over 70%) of the patients in the treatment group were taking the drug class of interest after one year. We included trials with both hypertensive and normotensive patients in this review if the majority (over 70%) of patients had elevated blood pressure, or the trial separately reported outcome data on patients with elevated blood pressure. </p> </section> <section id="CD001841-sec-0005"> <h3 class="title" id="CD001841-sec-0005">Data collection and analysis</h3> <p>The outcomes assessed were mortality, stroke, coronary heart disease (CHD), total cardiovascular events (CVS), decrease in systolic and diastolic blood pressure, and withdrawals due to adverse drug effects. We used a fixed‐effect model to to combine dichotomous outcomes across trials and calculate risk ratio (RR) with 95% confidence interval (CI). We presented blood pressure data as mean difference (MD) with 99% CI. </p> </section> <section id="CD001841-sec-0006"> <h3 class="title" id="CD001841-sec-0006">Main results</h3> <p>The 2017 updated search failed to identify any new trials. The original review identified 24 trials with 28 active treatment arms, including 58,040 patients. We found no RCTs for ARBs or alpha‐blockers. These results are mostly applicable to adult patients with moderate to severe primary hypertension. The mean age of participants was 56 years, and mean duration of follow‐up was three to five years. </p> <p>High‐quality evidence showed that first‐line low‐dose thiazides reduced mortality (11.0% with control versus 9.8% with treatment; RR 0.89, 95% CI 0.82 to 0.97); total CVS (12.9% with control versus 9.0% with treatment; RR 0.70, 95% CI 0.64 to 0.76), stroke (6.2% with control versus 4.2% with treatment; RR 0.68, 95% CI 0.60 to 0.77), and coronary heart disease (3.9% with control versus 2.8% with treatment; RR 0.72, 95% CI 0.61 to 0.84). </p> <p>Low‐ to moderate‐quality evidence showed that first‐line high‐dose thiazides reduced stroke (1.9% with control versus 0.9% with treatment; RR 0.47, 95% CI 0.37 to 0.61) and total CVS (5.1% with control versus 3.7% with treatment; RR 0.72, 95% CI 0.63 to 0.82), but did not reduce mortality (3.1% with control versus 2.8% with treatment; RR 0.90, 95% CI 0.76 to 1.05), or coronary heart disease (2.7% with control versus 2.7% with treatment; RR 1.01, 95% CI 0.85 to 1.20). </p> <p>Low‐ to moderate‐quality evidence showed that first‐line beta‐blockers did not reduce mortality (6.2% with control versus 6.0% with treatment; RR 0.96, 95% CI 0.86 to 1.07) or coronary heart disease (4.4% with control versus 3.9% with treatment; RR 0.90, 95% CI 0.78 to 1.03), but reduced stroke (3.4% with control versus 2.8% with treatment; RR 0.83, 95% CI 0.72 to 0.97) and total CVS (7.6% with control versus 6.8% with treatment; RR 0.89, 95% CI 0.81 to 0.98). </p> <p>Low‐ to moderate‐quality evidence showed that first‐line ACE inhibitors reduced mortality (13.6% with control versus 11.3% with treatment; RR 0.83, 95% CI 0.72 to 0.95), stroke (6.0% with control versus 3.9% with treatment; RR 0.65, 95% CI 0.52 to 0.82), coronary heart disease (13.5% with control versus 11.0% with treatment; RR 0.81, 95% CI 0.70 to 0.94), and total CVS (20.1% with control versus 15.3% with treatment; RR 0.76, 95% CI 0.67 to 0.85). </p> <p>Low‐quality evidence showed that first‐line calcium channel blockers reduced stroke (3.4% with control versus 1.9% with treatment; RR 0.58, 95% CI 0.41 to 0.84) and total CVS (8.0% with control versus 5.7% with treatment; RR 0.71, 95% CI 0.57 to 0.87), but not coronary heart disease (3.1% with control versus 2.4% with treatment; RR 0.77, 95% CI 0.55 to 1.09), or mortality (6.0% with control versus 5.1% with treatment; RR 0.86, 95% CI 0.68 to 1.09). </p> <p>There was low‐quality evidence that withdrawals due to adverse effects were increased with first‐line low‐dose thiazides (5.0% with control versus 11.3% with treatment; RR 2.38, 95% CI 2.06 to 2.75), high‐dose thiazides (2.2% with control versus 9.8% with treatment; RR 4.48, 95% CI 3.83 to 5.24), and beta‐blockers (3.1% with control versus 14.4% with treatment; RR 4.59, 95% CI 4.11 to 5.13). No data for these outcomes were available for first‐line ACE inhibitors or calcium channel blockers. The blood pressure data were not used to assess the effect of the different classes of drugs as the data were heterogeneous, and the number of drugs used in the trials differed. </p> </section> <section id="CD001841-sec-0007"> <h3 class="title" id="CD001841-sec-0007">Authors' conclusions</h3> <p>First‐line low‐dose thiazides reduced all morbidity and mortality outcomes in adult patients with moderate to severe primary hypertension. First‐line ACE inhibitors and calcium channel blockers may be similarly effective, but the evidence was of lower quality. First‐line high‐dose thiazides and first‐line beta‐blockers were inferior to first‐line low‐dose thiazides. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001841-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001841-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001841-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001841-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001841-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001841-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001841-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001841-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001841-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001841-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001841-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001841-abs-0009">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001841-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001841-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001841-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001841-abs-0005" lang="en"> <h3>Thiazides best first choice for hypertension</h3> <p><b>Review Question(s)</b> </p> <p>In this first update of a review published in 2009, we wanted to determine which drug class was the best first‐line choice in treating adult patients with raised blood pressure. </p> <p>We searched the available medical literature to find all the trials that compared the drugs to placebo or no treatment to assess this question. The data included in this review are up to date as of November 2017. </p> <p><b>Background</b> </p> <p>High blood pressure or hypertension can increase the risk of heart attacks and stroke. One of the most important decisions in treating people with elevated blood pressure is what drug class to use first. This decision has important consequences in terms of health outcomes and cost. </p> <p><b>Study characteristics</b> </p> <p>We found no new trials in this updated search. In the original review, we found 24 studies that randomly assigned 58,040 adult people (mean age 62 years) with high blood pressure, to four different drug classes or placebo<b>.</b> Duration of these studies ranged from three to five years. Drug classes studied included thiazide diuretics, beta‐blockers, ACE inhibitors, and calcium channel blockers. </p> <p><b>Key Results</b> </p> <p>We concluded that most of the evidence demonstrated that first‐line low‐dose thiazides reduced mortality, stroke, and heart attack. No other drug class improved health outcomes better than low‐dose thiazides. Beta‐blockers and high‐dose thiazides were inferior. </p> <p><b>Conclusions</b> </p> <p>High‐quality evidence supported that low‐dose thiazides should be used first for most patients with elevated blood pressure. Fortunately, thiazides are also very inexpensive. </p> <p><b>Quality of evidence</b> </p> <p>The evidence for first‐line low dose thiazides was high quality. For the other classes, we judged the evidence to be moderate or low quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001841-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001841-sec-0092"></div> <h3 class="title" id="CD001841-sec-0093">Implications for practice</h3> <section id="CD001841-sec-0093"> <p>Choice of first‐line treatment versus placebo or no treatment: the evidence for morbidity and mortality. </p> <p> <ul id="CD001841-list-0008"> <li> <p>Most of the available evidence justifying treatment of patients with elevated blood pressure used a thiazide as the first‐line drug. </p> </li> <li> <p>First‐line low‐dose thiazides were more effective than first‐line high‐dose thiazides and first‐line beta‐blockers. </p> </li> <li> <p>The treatment effect for first‐line ACE inhibitors was similar to low‐dose thiazides but less robust, and ACE inhibitors are more expensive than thiazides. </p> </li> <li> <p>Evidence for effectiveness of first‐line calcium channel blockers was insufficient.</p> </li> <li> <p>There were no RCTs comparing first‐line use of angiotensin receptor blockers or alpha blockers. </p> </li> <li> <p>Morbidity and mortality benefit with antihypertensive treatment depended on the drug class received, not the blood pressure achieved. </p> </li> </ul> </p> <p>Blood pressure measurement.</p> <p> <ul id="CD001841-list-0009"> <li> <p>Blood pressure must be measured (average of multiple readings) using proper technique, with the patient non‐stimulated and resting for at least five minutes. </p> </li> </ul> </p> <p>Population.</p> <p> <ul id="CD001841-list-0010"> <li> <p> Secondary prevention, survivors of transient ischemic attacks, stroke, or myocardial infarction, aged 55 to 80 years, with an average blood pressure of 155/94 mmHg (five‐year ARR 5.5%) (Moderate quality evidence). </p> </li> <li> <p>Primary prevention in adult patients with moderate to severe hypertension, with an average systolic blood pressure of 175 mmHg (five‐year ARR 5.1%) (High quality evidence). </p> </li> <li> <p>Primary prevention in adult patients with mild to moderate hypertension, with an average systolic blood pressure of 160 mmHg (five‐year ARR 0.8% to 1.2%) (Low quality evidence). </p> </li> <li> <p>Blood pressure targets are only achieved in about 60% of patients with mild, moderate, and severe hypertension treated with stepped‐care antihypertensive drugs. </p> </li> </ul> </p> </section> <h3 class="title" id="CD001841-sec-0094">Implications for research</h3> <section id="CD001841-sec-0094"> <p>At the present time, RCT data for antihypertensives as first‐line treatment versus placebo or no treatment are lacking for all classes other than thiazides. Since we have clear evidence of effectiveness of first‐line low‐dose thiazides in primary prevention, patients with blood pressure of 160/100 mmHg or higher, and in secondary prevention, in patients with lower blood pressures, it would be unethical to do further trials for this population compared to a placebo or untreated control group. Future RCTs in these populations should be done with low‐dose first‐line thiazides as the comparison group. The benefits and harms of primary prevention treatment of patients with lower blood pressures remains uncertain at the present time. Large trials recruiting primary prevention patients in lower blood pressure categories and using first‐line low‐dose thiazides compared to placebo are needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001841-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001841-sec-0029"></div> <div class="table" id="CD001841-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line low‐dose thiazide compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line low‐dose thiazide compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting: o</b> utpatients<br/> <b>Intervention:</b> First‐line low‐dose thiazide (mean duration 4.1 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative</b> </p> <p><b>effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of</b> </p> <p><b>participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Low dose</b> </p> <p><b>thiazide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (90 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.82 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,874<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.2%; NNTB = 83</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 per 1000<br/> (37 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.68<br/> (0.60 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,874<br/> (8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 2%; NNTB = 50</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total coronary heart disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72<br/> (0.61 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,022<br/> (7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 1.1%; NNTB = 91</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cardiovascular events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.64 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,022<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.9%; NNTB = 26</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/> (102 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.38<br/> (2.06 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8870<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 6.8%; NNTH = 15</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to risk of selective reporting bias; only 3 of the 8 studies reported withdrawal due to adverse effects </p> <p>2. Downgraded due to inconsistency; I² = 96%</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001841-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">First‐line high‐dose thiazide compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line high‐dose thiazide compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> First‐line high‐dose thiazide (mean duration 4.1 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative</b> </p> <p><b>effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with High dose</b> </p> <p><b>thiazide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.76 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (7 to 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/> (0.37 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1%; NNTB = 100</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (23 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.85 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000<br/> (32 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72<br/> (0.63 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,839<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 1.4%; NNTB = 71</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse</b> </p> <p><b>effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (84 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.48</p> <p>(3.83 to 5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,170<br/> ( 7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 7.6%; NNTH = 13</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Downgraded due to imprecision; wide confidence limits.</p> <p>2 Downgraded due to bias secondary to lack of blinding of investigators.</p> <p>3 Downgraded due to high risk of selective reporting bias as only 7 of the 11 trials report this outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001841-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">First‐line beta‐blocker compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line beta‐blocker compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> First‐line beta‐blocker (mean duration 5.3 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Beta‐</b> </p> <p><b>blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000<br/> (54 to 67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.86 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 0.6% NNTB = 167</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (34 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.78 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>76 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 1000<br/> (62 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89<br/> (0.81 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,313<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 0.8% NNTB = 125</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse</b> </p> <p><b>effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (129 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.59<br/> (4.11 to 5.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,565<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 11.3% NNTH = 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Downgraded due to imprecision; wide confidence limits</p> <p>2. Downgraded due to high risk of performance and detection bias.</p> <p>3. Downgraded due to inconsistency; I² &gt; 50%</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001841-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">First‐line angiotensin converting enzyme inhibitor compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line angiotensin converting enzyme (ACE) inhibitor compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> First‐line ACE inhibitor (mean duration 4.9 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ACE</b> </p> <p><b>inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (98 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.3%; NNTB = 43</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (31 to 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.52 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.1%; NNTB = 48</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (95 to 127) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.70 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5145<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.5%; NNTB = 40</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>201 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>153 per 1000<br/> (135 to 171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.76<br/> (0.67 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5145<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 4.8%; NNTB = 21</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to high risk of attrition and other bias.</p> <p>2. Downgraded due to imprecision (wide confidence interval).</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001841-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">First‐line calcium channel blocker compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line calcium channel blocker (CCB) compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> First‐line CCB (mean duration 2.5 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CCB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (41 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (14 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/> (0.41 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.5% NNTB = 67</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease (CHD)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (17 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77<br/> (0.55 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000<br/> (46 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71<br/> (0.57 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4695<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 2.4% NNTB = 42</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to imprecision (wide confidence intervals).</p> <p>2. Downgraded by 1 more level as there was only 1 trial</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001841-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001841-sec-0030"></div> <p>Elevated blood pressure (hypertension) is a chronic condition in which the blood pressure in the arteries is persistently elevated. It has been divided into three categories, based on resting blood pressures, measured in a standard way: mild hypertension (140 to 159/90‐99 mmHg), moderate hypertension (160 to 179/100 to 109 mmHg), and severe hypertension (180/110 mmHg or higher). Most people with high blood pressure have no signs or symptoms, even if blood pressure readings are very high. For most adults with primary or essential hypertension, there is no identifiable cause for the high blood pressure. Some people have high blood pressure, called secondary hypertension, caused by underlying conditions such as adrenal gland tumours, kidney problems, thyroid problems, excessive alcohol intake, or use of certain medications, such as birth control pills. Isolated systolic hypertension is a condition in which the diastolic pressure is normal (less than 90 mmHg), but systolic pressure is high (160 mmHg or greater). This is a common type of high blood pressure among older people. </p> <p>Blood pressure tends to increase with age. High blood pressure is more common in men in early middle age, more common in women after age 65, and more common in Blacks compared to Caucasians. The risk of high blood pressure is increased when there is a family history of high blood pressure, in the presence of obesity, or when physically inactive. High blood pressure is associated with smoking, too much salt in the diet, drinking excessive amounts of alcohol, high levels of stress, and chronic conditions such as diabetes, kidney disease, and sleep apnea. </p> <p>Uncontrolled persistent resting high blood pressure increases the risk of stroke, heart attack, heart failure, kidney damage, and vision loss. </p> <section id="CD001841-sec-0031"> <h3 class="title" id="CD001841-sec-0031">Description of the condition</h3> <p>When drug treatment is indicated in the management of patients with elevated blood pressure, an important decision is which drug to choose first. The decision should be informed by the best available evidence on reduction of the outcomes that are important to the patient, i.e. the ability of the drug to reduce the adverse health outcomes associated with elevated blood pressure (disabling stroke, myocardial infarction, heart failure, and mortality). </p> </section> <section id="CD001841-sec-0032"> <h3 class="title" id="CD001841-sec-0032">Description of the intervention</h3> <p>High blood pressure should initially be managed with changing life style — eating a healthy diet with less salt, exercising regularly, quitting smoking, and maintaining a healthy weight. When these life‐style changes are not enough, treatment with antihypertensive drugs is recommended. Several different classes of medications are available to reduce blood pressure. The six main drug classes, included in this review, are thiazide diuretics, beta‐blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, calcium channel blockers, and alpha blockers. </p> </section> <section id="CD001841-sec-0033"> <h3 class="title" id="CD001841-sec-0033">How the intervention might work</h3> <p>Different classes of antihypertensive drugs have different mechanisms of action.</p> <p><b>Thiazide and thiazide‐like diuretics</b>: The mechanism of action by which thiazide diuretics lower blood pressure in the long term is not fully understood (<a href="./references#CD001841-bbs2-0131" title='ZhuZ , ZhuS , LiuD , CaoT , WangL , TepelM . Thiazide‐like diuretics attenuate agonist‐induced vasoconstriction by calcium desensitisation linked to Rho kinase". Hypertension2005;45(2):233‐9. '>Zhu 2005)</a>. After chronic use, thiazides lower peripheral resistance. The mechanism of these effects is uncertain, as it may involve effects on the whole body, renal autoregulation, or direct vasodilator actions (<a href="./references#CD001841-bbs2-0102" title='HughesAD . "How do thiazide and thiazide‐like diuretics lower blood pressure?". J Renin Angiotensin Aldosterone Syst2004;5(4):155‐60. '>Hughes 2004</a>). Thiazides act on the kidney to inhibit reabsorption of sodium (Na<sup>+</sup>) and chloride (Cl<sup>‐</sup>) ions from the distal convoluted tubules in the kidneys, by blocking the thiazide‐sensitive sodium‐chloride symporter (<a href="./references#CD001841-bbs2-0094" title="DuarteJD , Cooper‐DeHoffRM . Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide‐like diuretics. Expert Rev Cardiovasc Ther.2010;8(6):793‐802. ">Duarte 2010</a>). They also increase calcium reabsorption at the distal tubule, and increase the reabsorption of calcium ions (Ca<sup>2+</sup>), by a mechanism involving the reabsorption of sodium and calcium in the proximal tubule in response to sodium depletion. </p> <p><b>Beta‐blockers</b>: Beta‐blockers are competitive antagonists that block the receptor sites for epinephrine (adrenaline) and norepinephrine on adrenergic beta‐receptors. Some block activation of all types of beta‐adrenergic receptors (β<sub>1</sub>, β<sub>2</sub>, and β<sub>3</sub>), and others are selective for one of the three types of beta receptors (<a href="./references#CD001841-bbs2-0095" title="FrishmanW.H , Cheng‐LaiA , NawarskasJ . Current Cardiovascular Drugs. Fourth. Current Science Group, 2005:153. ">Frishman 2005</a>). </p> <p><b>Angiotensin converting enzyme (ACE) inhibitors</b>: ACE inhibitors block the conversion of angiotensin I (AI) to angiotensin II (AII), and thus decrease the actions of angiotensin II. The end result is to lower arteriolar resistance and increase venous capacity; decrease cardiac output, cardiac index, stroke work, and volume; lower resistance in blood vessels in the kidneys; and increase excretion of sodium in the urine. Renin and AI increases in concentration in the blood as a result of negative feedback of the conversion of AI to AII. AII and aldosterone levels decrease. Bradykinin increases, because ACE is also responsible for inactivation of bradykinin. </p> <p><b>Angiotensin receptor blockers (ARBs):</b> ARBs block the activation of angiotensin II AT<sub>1</sub> receptors. Blockage of AT<sub>1</sub> receptors directly causes vasodilation, reduces secretion of vasopressin, and reduces the production and secretion of aldosterone. </p> <p><b>Calcium channel blockers (CCBs)</b>: CCBs block calcium channel and inhibit calcium ion influx into vascular smooth muscle and myocardial cells. They reduce blood pressure through various mechanisms: by vasodilation, by reducing the force of contraction of the heart, by slowing the heart rate, and by directly reducing aldosterone production. </p> <p><b>Alpha blockers:</b> α<sub>1</sub> adrenergic receptor blockers inhibit the binding of norepinephrine (noradrenaline) to the α<sub>1</sub> receptors on vascular smooth muscle cells. The primary effect of this inhibition is vasodilation, which decreases peripheral vascular resistance, leading to decreased blood pressure. </p> </section> <section id="CD001841-sec-0034"> <h3 class="title" id="CD001841-sec-0034">Why it is important to do this review</h3> <p>There have been a number of reviews of the effectiveness of antihypertensive therapy, but most have emphasized effectiveness of all drug classes (<a href="./references#CD001841-bbs2-0092" title="Collins , R , Peto , R , Macmahon , S , Hebert , P , Fiebach , N.H , Eberlein , k.A , Godwin , J , Qizilbash , N , Taylor , J.O , Hennekens , C.H . Blood pressure, stroke, and coronary heart disease‐ Part 2. Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827‐38. [MEDLINE: 90205389] ">Collins 1990</a>; <a href="./references#CD001841-bbs2-0098" title="Gueyffier F. FromentA , GoutonM . New meta‐analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Human Hyperten1996;10:1‐8. [MEDLINE: 96219361] ">Gueyffier 1996</a>), or effectiveness of all drug classes in special populations, such the elderly (<a href="./references#CD001841-bbs2-0103" title="Insua JT. Sacks HS. Lau TS. LauJ , et al. Drug treatment of hypertension in the elderly: A meta‐analysis. Ann Intern Med1994;121:355‐62. [MEDLINE: 94317871] ">Insua 1994</a>; <a href="./references#CD001841-bbs2-0107" title="MacMahonS , RogersA . The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exper Hypertension1993;15(6):967‐78. [Accession number 1993344587] ">MacMahon 1993</a>; <a href="./references#CD001841-bbs2-0108" title="MulrowCD , CornellJA , HerreraCR , KadriA , et al. Hypertension in the elderly: Implications and generalizability of randomized trials. JAMA1994;272:1932‐8. [MEDLINE: 95082133] ">Mulrow 1994</a>; <a href="./references#CD001841-bbs2-0109" title="MulrowC , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a>; <a href="./references#CD001841-bbs2-0124" title="Thijs L. Fagard R. Lijnen P. StaessenJ , et al. A meta‐analysis of outcome trials in elderly hypertensives. Journal of Hypertension1992;10:1103‐9. [MEDLINE: 93107678] ">Thijs 1992</a>). When all drug therapies are included in one review, there is an underlying assumption that the benefits of lowering blood pressure are independent of the mechanism by which it is achieved. This assumption has not been proven, and it is likely that different classes of drugs will have different blood pressure lowering effects, and will have effects that are independent of the blood pressure lowering effect. A drug that lowers blood pressure could have pharmacological and physiological actions independent of blood pressure lowering, and these other actions (both known and unknown) could enhance or negate the effects on health outcomes associated with the decrease in blood pressure. This possibility is supported by a recent analysis that suggested that blood pressure lowering only explains about 50% of the treatment effect in antihypertensive trials (<a href="./references#CD001841-bbs2-0089" title="BoisselJP , GueyffierF , BoutitieF , PocockS , FagardR . Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments.. Fund Clin Pharmacol2005;19:579‐584. ">Boissel 2005</a>). </p> <p>This review update aims to 1) document the best available evidence of effectiveness for different classes of drugs and doses used as first‐line therapy, compared to placebo or no treatment, and 2) present the outcome data in a way that best assists clinicians in the choice of a first‐line drug. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001841-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001841-sec-0035"></div> <section id="CD001841-sec-0036"> <h3 class="title" id="CD001841-sec-0036">Primary objective</h3> <p> <ol id="CD001841-list-0001"> <li> <p>To quantify the mortality and morbidity effects from different first‐line anti‐hypertensive drug classes: thiazides (low dose and high dose), beta‐blockers, calcium channel blockers, ACE inhibitors, angiotensin II receptor blockers, and alpha‐blockers, compared to placebo or no treatment. </p> </li> </ol> </p> </section> <section id="CD001841-sec-0037"> <h3 class="title" id="CD001841-sec-0037">Secondary objectives</h3> <p> <ol id="CD001841-list-0002"> <li> <p>To quantify the blood pressure lowering effect of antihypertensive treatment when different drug classes are used as the first‐line drug. </p> </li> <li> <p>To quantify the rate of withdrawal due to adverse drug effects of different first‐line antihypertensive class drugs, compared to placebo or no treatme </p> </li> </ol> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001841-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001841-sec-0038"></div> <section id="CD001841-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001841-sec-0040"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCT) of at least one year duration. The comparative group was a placebo, or an untreated control. We required the following data from the trial: baseline patient characteristics, clearly defined morbidity and mortality endpoints, and outcome data presented using the intention‐to‐treat principle. </p> <p>We excluded trials using other than randomized allocation methods, such as alternate allocation, week of presentation, or retrospective controls. We also excluded trials that compared two specific antihypertensive first‐line therapies without a placebo or untreated control. </p> </section> <section id="CD001841-sec-0041"> <h4 class="title">Types of participants</h4> <p>Blood pressure was measured using proper technique at least two times, with the patient resting for at least five minutes. All patients must have had a baseline resting blood pressure of at least 140 mmHg systolic or a diastolic blood pressure of at least 90 mmHg. Trials that included both hypertensive and normotensive patients were acceptable if the majority (&gt; 70%) of patients had elevated blood pressure, or the trial separately reported outcome data on patients with elevated blood pressure. Trials were not limited by any other factor or baseline risk. It was assumed that age and comorbidities did not affect the risk ratio <b>of outcomes</b> associated with drug treatment. </p> </section> <section id="CD001841-sec-0042"> <h4 class="title">Types of interventions</h4> <p>Treatment was to be clearly defined as a specific class of first‐line antihypertensive therapy in one of the following classes: thiazide diuretics, beta blockers, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or alpha adrenergic blockers. The majority (&gt; 70%) of the patients in the treatment group were to be taking the drug class of interest after one year. We allowed initial combined therapies with drug classes not in the defined categories. We also allowed supplemental drugs from other drug classes of interest as stepped therapy, but only as long as they were not taken by over 50% of the patients. We assumed that these supplemental drugs did not systematically interact to affect the occurrence of the outcomes studied.<br/> We also stratified the analysis by the thiazide dose. We classified thiazide doses as high‐dose and low‐dose by selecting hydrochlorothiazide as the standard, and translating the doses of other drugs in the class into hydrochlorothiazide equivalents. We assumed that each thiazide had a similar dose‐response curve, and the usual prescription dose range represented a similar range on the dose‐response curve. </p> <p>We classified groups according to the starting dose in the trial:</p> <section id="CD001841-sec-0043"> <h5 class="title">High‐dose thiazide group: starting dose</h5> <p> <ul id="CD001841-list-0003"> <li> <p>hydrochlorothiazide ≥ 50 mg per day</p> </li> <li> <p>chlorothiazide ≥ 500 mg per day</p> </li> <li> <p>chlorthalidone ≥ 50 mg per day</p> </li> <li> <p>bendrofluazide ≥ 5 mg per day</p> </li> <li> <p>methylclothiazide ≥ 5 mg per day</p> </li> <li> <p>trichlormethiazide ≥ 2 mg per day</p> </li> <li> <p>indapamide ≥ 5 mg per day</p> </li> </ul> </p> </section> <section id="CD001841-sec-0044"> <h5 class="title">Low‐dose thiazide group: starting dose</h5> <p> <ul id="CD001841-list-0004"> <li> <p>hydrochlorothiazide &lt; 50 mg per day</p> </li> <li> <p>chlorthiazide &lt; 500 mg per day</p> </li> <li> <p>chlorthalidone &lt; 50 mg per day</p> </li> <li> <p>bendrofluazide &lt; 5 mg per day</p> </li> <li> <p>methylclothiazide &lt; 5 mg per day</p> </li> <li> <p>trichlormethiazide &lt; 2 mg per day</p> </li> <li> <p>indapamide &lt; 5 mg per day</p> </li> </ul> </p> <p>We calculated the average dose in the high‐dose and low‐dose group as a weighted average from the trials in which the average dose was reported, or could be estimated. </p> </section> </section> <section id="CD001841-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD001841-sec-0046"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001841-list-0005"> <li> <p>Total mortality (death from all causes)</p> </li> <li> <p>Total stroke (fatal and non‐fatal strokes)</p> </li> <li> <p>Total coronary heart disease (CHD; fatal and non‐fatal myocardial infarction, and sudden or rapid cardiac death). </p> </li> <li> <p>Total cardiovascular events (total stroke, total CHD, hospitalization or death from congestive heart failure and other significant vascular deaths, such as ruptured aneurysms. It does not include angina, transient ischemic attacks, surgical or other procedures, or accelerated hypertension). </p> </li> </ol> </p> <p>When the primary trials did not report outcomes that fit the above definitions, we based our decisions on maximizing the inclusion of the data and maintaining concordance, with how the data were classified in previous reviews. We assumed that the effect of antihypertensive treatment on outcomes was independent of whether elevated blood pressure was defined in terms of systolic or diastolic pressure. </p> </section> <section id="CD001841-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001841-list-0006"> <li> <p>Reduction in systolic and diastolic blood pressure during the first year</p> </li> <li> <p>Patient withdrawal due to adverse drug effects</p> </li> </ol> </p> </section> </section> </section> <section id="CD001841-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001841-sec-0049"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist (DS) conducted systematic searches in the following databases for RCTs without language, publication year, or publication status restrictions: </p> <p> <ul id="CD001841-list-0007"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS‐Web; searched 24 November 2017); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS‐Web; searched 24 November 2017); </p> </li> <li> <p>MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 24 November 2017); </p> </li> <li> <p>Embase Ovid (searched 24 November 2017);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 24 November 2017); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>; searched 24 November 2017). </p> </li> </ul> </p> <p>The Cochrane Hypertension Information Specialist (DS) modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomized controlled (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Box 6.4.b; <a href="./references#CD001841-bbs2-0100" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org, 2011. ">Higgins 2011a</a>). The MEDLINE search strategy was translated into the other databases using the appropriate controlled vocabulary, as applicable (<a href="./appendices#CD001841-sec-0098">Appendix 1</a>). </p> </section> <section id="CD001841-sec-0050"> <h4 class="title">Searching other resources</h4> <p>We used previously published meta‐analyses on the treatment of hypertension to help identify references to trials (<a href="./references#CD001841-bbs2-0088" title="TurnbullF , NealB , AlbertC , ChalmersJ , ChapmanN , CutlerJ , WoodwardM , MacMahon S: Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.. Arch Intern Med2005;165(12):1410‐1419. [MEDLINE: 15983291] ">BBLTTC 2005</a>; <a href="./references#CD001841-bbs2-0090" title="Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure‐lowering drugs: results of prospectively designed overviews of randomised trials. Lancet2000;355:1955‐64. ">BPLTTC 2000</a>; <a href="./references#CD001841-bbs2-0092" title="Collins , R , Peto , R , Macmahon , S , Hebert , P , Fiebach , N.H , Eberlein , k.A , Godwin , J , Qizilbash , N , Taylor , J.O , Hennekens , C.H . Blood pressure, stroke, and coronary heart disease‐ Part 2. Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827‐38. [MEDLINE: 90205389] ">Collins 1990</a>; <a href="./references#CD001841-bbs2-0096" title="GoeresLM , EckstromE , LeeDS . Pharmacotherapy for Hypertension in Older Adults: A Systematic Review. Drugs Aging2014;31:897‐910. ">Goeres 2014</a>; <a href="./references#CD001841-bbs2-0098" title="Gueyffier F. FromentA , GoutonM . New meta‐analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Human Hyperten1996;10:1‐8. [MEDLINE: 96219361] ">Gueyffier 1996</a>; <a href="./references#CD001841-bbs2-0099" title="GueyffierF , BulpittC , BoisselJP , SchronE , EkbomT , et al. for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta‐analysis of randomised controlled trials. Lancet1999;353:793‐96. ">Gueyffier 1999</a>; <a href="./references#CD001841-bbs2-0103" title="Insua JT. Sacks HS. Lau TS. LauJ , et al. Drug treatment of hypertension in the elderly: A meta‐analysis. Ann Intern Med1994;121:355‐62. [MEDLINE: 94317871] ">Insua 1994</a>; <a href="./references#CD001841-bbs2-0104" title="KangS , WuFY , AnN , RenM . A Systematic Review and Meta‐Analysis of the Efficacy and Safety of a Fixed,Low‐Dose Perindopril‐Indapamide Combination as First‐Line Treatment of Hypertension. Clinical Therapeutics2004;26(2):257‐70. ">Kang 2004</a>; <a href="./references#CD001841-bbs2-0105" title="KızılırmakP , UresinY , OzdemirO , KilickiranB , et al. Renin‐angiotensin‐aldosterone system blockers and cardiovascular outcomes: a meta‐analysis of randomized clinical trials [Renin‐anjiyotensin‐aldosteron sistemi blokerleri ve kardiyovasküler sonuçları: Randomize klinik çalışmaların meta‐analizi]. Turk Kardiyol Dern Ars2017;45(1):49‐66. [DOI: 10.5543/tkda.2016.78006] ">Kızılırmak 2017</a>; <a href="./references#CD001841-bbs2-0106" title="LawMR , MorrisJK , WaldNJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‐analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665. ">Law 2009</a>; <a href="./references#CD001841-bbs2-0107" title="MacMahonS , RogersA . The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exper Hypertension1993;15(6):967‐78. [Accession number 1993344587] ">MacMahon 1993</a>; <a href="./references#CD001841-bbs2-0108" title="MulrowCD , CornellJA , HerreraCR , KadriA , et al. Hypertension in the elderly: Implications and generalizability of randomized trials. JAMA1994;272:1932‐8. [MEDLINE: 95082133] ">Mulrow 1994</a>; <a href="./references#CD001841-bbs2-0109" title="MulrowC , LauJ , CornellJ , BrandM . Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000028] ">Mulrow 1998</a>; <a href="./references#CD001841-bbs2-0110" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy of hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>; <a href="./references#CD001841-bbs2-0112" title="NikolausT , SommerN , BeckerC . Treatment of arterial hypertension with diuretics, beta‐ and calcium channel blockers in old patients. Z Gerontol Geriat2000;33:427‐32. ">Nikolaus 2000</a>; <a href="./references#CD001841-bbs2-0113" title="ParsonsC , MuradMH , AndersenS , MookadamF , LabonteH . The effect of antihypertensive treatment on teh incidence of stroke and cognitive decline in the elderly: a meta‐analysis. Future Cardiology2016;12(2):237‐48. ">Parsons 2016</a>; <a href="./references#CD001841-bbs2-0114" title="PearceKA , FurbergCD , RushingJ . Does Antihypertensive Treatment of the Elderly Prevent Cardiovascular Events or Prolong Life? A Meta‐analysis ofHypertension Treatment Trials. Archives of Family Medicine1995;4:943‐50. ">Pearce 1995</a>; <a href="./references#CD001841-bbs2-0115" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis.. JAMA1997;277:739‐745. [MEDLINE: 97195474] ">Psaty 1997</a>; <a href="./references#CD001841-bbs2-0116" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , WeissNS . Health outcomes associated with various antihypertensive therapies used as first‐line agents: A network meta‐analysis. JAMA2003;289:2534‐2544. ">Psaty 2003</a>; <a href="./references#CD001841-bbs2-0118" title="QuanA , KerlikowskeK , GueyffierF , Boissel JP and INDANA investigators. Efficacy of Treating Hypertension in Women. J General Internal Medicine1999;14:718‐29. ">Quan 1999</a>; <a href="./references#CD001841-bbs2-0121" title="Sundstro¨mJ , ArimaH , JacksonR , TurnbullF , et al. Effects of Blood Pressure Reduction in Mild Hypertension. A Systematic Review and Meta‐analysis. Annals of Internal Medicine2015;162:184‐191. ">Sundstro¨m 2015</a>; <a href="./references#CD001841-bbs2-0122" title="Tan Xue‐Ying , HuJing‐Bo . ACEIs/ARBs for the prevention of type 2 diabetes in patients with cardiovascular diseases: a systematic review and meta‐analysis. Int J Clin Exp Med2016;9(5):7624‐37. ">Tan 2016</a>; <a href="./references#CD001841-bbs2-0124" title="Thijs L. Fagard R. Lijnen P. StaessenJ , et al. A meta‐analysis of outcome trials in elderly hypertensives. Journal of Hypertension1992;10:1103‐9. [MEDLINE: 93107678] ">Thijs 1992</a>; <a href="./references#CD001841-bbs2-0125" title="ThomopoulosC , ParatiG , Zanchetti . A . Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta‐analyses, and meta‐regression analyses of randomized trials. Journal of Hypertension2014;32(12):2285‐95. ">Thomopoulos 2014</a>; <a href="./references#CD001841-bbs2-0126" title="Thomopoulos , C , Parati , G , Zanchetti , A . Effects of blood pressure‐lowering treatment. 6. Prevention of heart failure and new‐onset heart failure ‐ Meta‐analyses of randomized trials. Journal of HypertensionMarch 2016;34(3):373‐84. ">Thomopoulos 2016</a>; <a href="./references#CD001841-bbs2-0127" title="Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet2003;362:1527‐35. ">Turnbull 2003</a>; <a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a>; <a href="./references#CD001841-bbs2-0130" title="Zanchetti , A , Thomopoulos , C , Parati , G . Randomized Controlled Trials of Blood Pressure Lowering in Hypertension: A Critical Reappraisal. Circulation Research2015;116(6):1058‐73. ">Zanchetti 2015</a>). We carefully screened the bibliographies from these systematic reviews to make sure that any study that met the inclusion criteria was not missed. </p> <p>We contacted experts in the field to identify any other trials we may have missed in our search. We checked reference lists of included studies, and contacted relevant individuals for information about unpublished or ongoing studies. </p> </section> </section> <section id="CD001841-sec-0051"> <h3 class="title" id="CD001841-sec-0051">Data collection and analysis</h3> <section id="CD001841-sec-0052"> <h4 class="title">Selection of studies</h4> <p>We rejected articles on the initial screening if we could determine from the title or the abstract that the article was not a report of a randomized controlled trial, or that there was no possibility that the trial would fit the requirements of this review. Of the articles selected for further review, two reviewers (JMW and VM) independently assessed whether they would be included or excluded. </p> </section> <section id="CD001841-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>The data abstraction form included details of study design, randomization, blinding, duration of treatment, baseline characteristics, number of patients lost to follow‐up, outcomes, intervention, statistical analysis, and reporting. Two reviewers (JMW and VM) independently extracted the data, cross‐checked, and compared, whenever possible, to data from previously published meta‐analyses. We detailed trial characteristics in the '<a href="./references#CD001841-sec-0113" title="">Characteristics of included studies</a>' table. We detailed trials that were excluded in the '<a href="./references#CD001841-sec-0114" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD001841-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (VM and RG) independently assessed risk of bias of each included trial; a third review author (JMW) sorted any disagreements. We assessed risk of bias according to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001841-bbs2-0101" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org, 2011. ">Higgins 2011b</a>). We assessed seven domains: randomization and allocation concealment to assess selection bias; blinding of the participants and physician to assess performance bias; blinding of the outcome assessor to assess detection bias; incomplete outcome reporting to assess attrition bias; selective reporting of outcomes to assess selective reporting bias; and we added an additional category ‐ other bias, to assess whether the study was funded by the manufacturer and conflict of interest was present, which we assessed as high risk of bias, since it has been shown to overestimate treatment effect. </p> <section id="CD001841-sec-0055"> <h5 class="title">'Summary of findings' table</h5> <p>We used GRADEpro GDT software to present the 'Summary of findings' table (<a href="./references#CD001841-bbs2-0097" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). We decided to include all clinically relevant primary and secondary outcomes: total mortality, total stroke, total coronary heart disease, total cardiovascular events, and withdrawal due to adverse events. We did not include the magnitude of systolic and diastolic blood pressure reduction. </p> <p>We considered five factors in grading the overall quality of evidence: limitations in study design and implementation, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision in results, and high probability of publication bias. This approach specifies four levels of quality: high‐, moderate‐, low‐, and very low‐quality evidence. The highest quality rating is for randomized trial evidence. Quality rating is downgraded by one level for each factor, up to a maximum of three levels for all factors. If there are severe problems for any one factor (when assessing limitations in study design and implementation, in concealment of allocation, loss of blinding, or attrition over 50% of participants during follow‐up), randomized trial evidence may fall by two levels due to that factor alone. </p> </section> </section> <section id="CD001841-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5 for data synthesis and analyses (<a href="./references#CD001841-bbs2-0120" title="Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We based quantitative analyses of outcomes on intention‐to‐treat results. We used risk ratios (RR) with 95% confidence intervals (CI) to combine outcomes across trials. If there was a significant difference in any outcome measure, we presented an absolute risk reduction (ARR), and number needed to treat for an additional beneficial (NNTB) or harmful (NNTH) outcome in the 'Summary of findings' table. This estimate, with 95% confidence intervals (CI), is considered the best estimate of the average benefit and the range of that benefit in populations with different baseline risks. </p> <p>For continuous outcomes (systolic and diastolic blood pressure), we calculated the mean difference (MD) with 99% CI to combine outcomes across studies. Systolic and diastolic blood pressure readings were taken at one year, or the earliest time after one year, to include the data from the maximum number of randomized patients. Mean blood pressure values only reflected data for patients in whom blood pressure was measured. We used standard deviation of the change (SD) at one year if available. </p> </section> <section id="CD001841-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <p>For all outcomes measures reported, we used data from each trial at the end of the follow‐up period mentioned in each trial, which varied from 1.1 to 10 years. </p> </section> <section id="CD001841-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>When participants were lost to follow‐up, we used data as reported for participants who were followed until the end of the study, in the analyses. We outlined how data were accounted for and included in each study under assessment of attrition bias in the '<a href="#CD001841-sec-0069">Risk of bias in included studies</a>' table. </p> <p>For example, in the <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> study, for events such as non‐fatal stroke or myocardial infarction, which terminated participation in the study, the investigators did not follow‐up these participants to the end of the study. In such instances, investigators included data available up to the time point during which participants were followed in the analyses. </p> <p>If the SD value for reduction in systolic and diastolic blood pressure was not reported at one year, we imputed the SD of the change at other time points during treatment. If the SD of the change was not available at all, we imputed the SD of the endpoint systolic or diastolic blood pressure. In cases where these values were also missing, we imputed the mean weighted SD of the change from other trials. This imputation is a limitation, and to reduce the impact of this limitation, we used a 99% level of significance for the blood pressure measurements, instead of the standard 95%. </p> </section> <section id="CD001841-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity of treatment effect between the trials using a standard Chi² statistic for heterogeneity. We used the fixed‐effect model to obtain summary statistics of pooled trials, unless there was significant between‐study heterogeneity, in which case we used the random‐effects model to test statistical significance. </p> </section> <section id="CD001841-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>For each study, we evaluated whether selective reporting of outcomes was suspected. In the case of suspected reporting bias, we contacted study authors for clarification. </p> <p>We had planned to use a funnel plot to assess the possibility of publication bias for outcomes that were reported in 10 or more studies. A test for funnel plot asymmetry (small study effects) formally examines whether the association between estimated intervention effects and a measure of study size is greater than might be expected to occur by chance. </p> </section> <section id="CD001841-sec-0061"> <h4 class="title">Data synthesis</h4> <p>We used Review Manager 5 to perform data synthesis and analyses (<a href="./references#CD001841-bbs2-0120" title="Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We presented dichotomous outcomes as RR with 95% CI using a fixed‐effect model, and continuous outcomes (systolic and diastolic blood pressure) as MD with 99% CI. </p> </section> <section id="CD001841-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroup analyses: different race: Black versus Caucasian versus Asian; and baseline severity of hypertension: mild, moderate, severe. Unfortunately, it was not possible to do any subgroup analyses, because there were a lack of data specific to race, and most trial participants had moderate to severe hypertension, but data were not available separately. </p> <p>When heterogeneity was significant (I² greater than 50%), we attempted to identify trials that would contribute to heterogeneity, and explore their population characteristics, baseline blood pressure, blinded or open‐label study design, use of antihypertensive drugs as fixed dose or stepped‐up therapy, or response to placebo that would possibly explain the reason for heterogeneity. As the decrease in systolic and diastolic blood pressure showed significant heterogeneity, we present results as MD with 99% CI using both a fixed‐effect as well as random effect model. </p> </section> <section id="CD001841-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>To test for robustness of results, we conducted several sensitivity analyses. This was done by deselecting trials in the following categories: trials that were not placebo‐controlled and blinded, trials restricted to patients with isolated systolic hypertension, trials that enrolled more than 80% of patients with previous stroke, and myocardial infarction of peripheral vascular disease (secondary prevention), trials using combined starting drugs, and trials using supplemental drugs from other defined classes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001841-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001841-sec-0064"></div> <section id="CD001841-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD001841-sec-0066"> <h4 class="title">Results of the search</h4> <p>The initial search up to 2009 resulted in 6232 citations, 5985 of which we excluded on reading titles and abstracts. We retrieved 247 citations for more detailed evaluation, 13 of which were review articles. We further evaluated 234 reports; we included 127 reports of 24 trials, and excluded 107 reports. </p> <p>The updated search in November 2017 resulted in 11,855 citations. We screened the titles and abstracts of these citations, and found 11,500 to be irrelevant. We requested the full text of 355 citations, but none of them met the minimum inclusion criteria. We found 6 additional reports of previously included studies. </p> <p>For this update of a total of 87 potential trials identified, we included 133 reports of 24 trials, (58,040 patients), and excluded 63 trials. Refer to <a href="#CD001841-fig-0001">Figure 1</a> for study flow diagram. </p> <div class="figure" id="CD001841-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD001841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD001841-sec-0067"> <h4 class="title">Included studies</h4> <p>We found 24 trials, with 28 active treatment arms, studying 58,040 patients, which met the inclusion criteria. Trials were only available to evaluate the effectiveness of four drug classes as first‐line drugs thiazides (19 trials in 39,713 patients), beta‐blockers (five trials in 19,313 patients), ACE inhibitors (three trials in 6002 patients), and calcium channel blockers (one trial in 4695 patients). Two trials evaluated thiazides as well as beta‐blockers versus placebo (<a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>;); <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> evaluated beta‐blockers as well as ACE inhibitors versus placebo, and <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a> evaluated thiazides as well as ACE inhibitors versus placebo, making 28 total comparisons from 24 trials. We did not identify any randomized controlled trials that compared first‐line alpha‐adrenergic blockers or angiotensin receptor blockers to placebo or untreated control group. </p> <p>The average age of participants across all included trials was 62 years. Six trials were limited to patients over 60 years of age (<a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>). The age range in other trials was between 21 and 80 years. The mean age of patients from the four classes was: thiazide ‒ 61 years, beta‐blockers ‒ 56 years, ACE inhibitors ‒ 67 years, and calcium channel blockers ‒ 70 years. </p> <p>Most participants were recruited from Western industrialized countries. Two trials did not report percentage of participants from different countries (<a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>). In 22 trials reporting recruitment of participants, 7750 (15.5%) were from USA, 32,907 (66%) from Europe; 3427 (6.9%) from Australia, and 91 (0.2%) from Japan. Females represented 45% of the population studied. Four trials included only men (<a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>) . </p> <p>Fourteen trials did not report ethnicity (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>). Ten trials reported ethnicity. African‐Americans comprised the following percentages in these trials: <a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a> (0%), <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (80%), <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> (13.8%), <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (18%), <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> (7.6%), <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> (28%), <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a> ( 53.8%), <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a> (42%), <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a> (25%), and <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a> (89.6%). </p> <p>The study population consisted of predominantly ambulatory patients recruited from the community, primary care centres, or hospital‐based clinics in 22 trials (57,982 patients, 99.7% of all patients included in this review). In the <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a> trial, 91 (0.2% of total) subjects were recruited from a home for the aged. <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a> recruited 97 (0.3% of total) participants admitted to the hospital, who had survived an ischemic‐type major stroke. </p> <p>In most trials, it was possible to determine whether the participants in the trials represented primary or secondary prevention. All trials excluded patients with angina and congestive heart failure, as these conditions would require use of antihypertensive drugs for reasons independent of their antihypertensive action. Some trials allowed patients with prior myocardial infarction or stroke, as long as they were not recent (e.g. within the previous three months). Thus, by determining the baseline prevalence of stroke and myocardial infarction, it was possible to calculate the percentage that represented secondary prevention. Three trials did not report prevalence of stroke or myocardial infarction, but it was likely low in these trials (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; 587 participants, (1.0% of total randomized participants). Six trials (11,157 patients) were primary prevention with less than 1% secondary prevention patients (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a> (0.4%); <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> (0%); <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a> (0%); <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> (0%); <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> (0%); and <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a> (0%). Six trials (12,042 patients) were secondary prevention (<a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a> (100%); <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a> (88%); <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a> (96%); <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a> (0%); <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a> (100%); and <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a> (100%). Nine trials (34,041 patients) were mostly primary prevention patients (<a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a> (it was reported that the baseline prevalence of cardiovascular complications was 36% and these included conditions other than proven myocardial infarction and stroke); <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a> (12%); <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a> (7%); <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> (2.2%); <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> (6.4%); <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (5.5%); <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a> (reported as 30% patients with cardiovascular complications); <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a> (7%);and <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a> (29%). The percentage of secondary patients in the 10 mostly primary prevention trials was 3212 (5.6%) of total randomized patients. </p> <p>Thus, since 42,196 (72.7%) of total randomized people were primary prevention, the conclusions from this review are primarily relevant to the primary prevention setting. </p> <p>Baseline prevalence of diabetes was reported in 8 trials as follows: <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a> (38%); <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a> (7%); <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> (0%); <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> (10.1%); <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> (100%); <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> (0%); <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a> (9.1%); and <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a> (16.0%). Baseline prevalence of smoking was as follows: <a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a> (25.0%); <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a> (16.0%); <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a> (6.5%); <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a> (41.7%); <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a> (28.5%); <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a> (36.0%); <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> (13.0%); <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a> (11.0%); <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a> (7.0%); <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> (22.3%); and <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> (46.7%). </p> <p>Recent trials defined stroke as the presence of neurological deficit lasting for more than 24 hours. It includes some patients with no disability. Older trials, like the <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>, defined stroke as a neurological deficit lasting more than 24 hours, or a marked increase in transient ischemic attacks (twice the weekly pre‐randomization level of occurrence, more than four per week, or deterioration of more than eight points in neurological score). <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a> defined stroke as typical weakness or paralysis. In some trials, stroke was not defined. In our opinion, lumping all strokes, including reversible ischemic neurological deficit (RIND), into one outcome is not optimal. More clinically relevant interpretations could be made if strokes were subdivided into three groups: strokes with no disability, strokes with mild disability, and strokes with severe disability. Myocardial infarction and sudden death were defined consistently across most trials. Myocardial infarction was defined as typical chest pain with ECG changes or increased cardiac enzymes; sudden death was defined as death within 24 hours of first evidence of acute cardiovascular disease, or unrelated to other known pre‐existing diseases. </p> <p>Five trials restricted recruitment to persons with systolic hypertension; defined as systolic pressure 160 to 219 mmHg, and diastolic pressure less than 90 mmHg (<a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>), diastolic pressure less than 95 mmHg (<a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>), or systolic pressure higher than 140 mmHg (<a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>), or higher than 160 mmHg (<a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>). Six trials based entry on diastolic hypertension (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>); and 10 trials based entry on either systolic or diastolic hypertension (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a> represented the subgroup of the HOPE trial that had a baseline blood pressure higher than 140 mmHg systolic, or higher than 90 mmHg diastolic. Two trials were included because more than 70% of patients at entry had a systolic BP higher than 140 mmHg (<a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>). </p> <p>Weighted mean baseline blood pressure for all the trials was 168/94 mmHg. When this was broken down into those that used systolic blood pressure as entry criteria, it was 173/84 mmHg; for those using diastolic pressure as entry criteria, it was 162/106 mmHg; and for those using both systolic and diastolic pressure as entry criteria, it was 167/97 mmHg. Two trials did not report baseline systolic pressure levels (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>;<a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>), and one trial did not report baseline diastolic pressure levels (<a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>). </p> <p>For complete description of the blood pressure inclusion criteria for each study, see 'Participants' in the '<a href="./references#CD001841-sec-0113" title="">Characteristics of included studies</a>' table. </p> <p>A stepped approach to antihypertensive drug administration was used in 18 of the 24 trials. The exceptions were <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; and <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>, which used a standard dose of drug in the intervention arm. In 19 of the trials, a thiazide was the first‐line therapy in one of the arms of the trial. Because of a relatively large amount of data for thiazides, we were able to divide these 19 trials into those in which the thiazide starting dose was defined as low (8/19 trials, 874 patients) or high (11/19 trials, 19,839 patients), as explained in the methods. Three of the trials did not specify the thiazide dose, but were included in the high‐dose group because prescribing high doses of thiazides was common when those trials were conducted (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>). The weighted mean dose of thiazide, in hydrochlorothiazide equivalents, was 90 mg for the high‐dose trials and 24 mg for the low‐dose trials. In five trials, a beta‐blocker was used as first‐line therapy in one of the arms of the trial (<a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). Three trials used an angiotensin converting enzyme inhibitor, (<a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). One trial used the calcium channel blocker nitrendipine (<a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>). Second‐ and third‐line drugs included beta‐blockers, centrally‐acting drugs, peripherally‐acting anti‐adrenergic agents, vasodilators, thiazides, ACE inhibitors, alpha blockers, calcium channel blockers, and loop diuretics. See 'Interventions' in the '<a href="./references#CD001841-sec-0113" title="">Characteristics of included studies</a>' table for a complete description of each study's drug treatment protocol. </p> <p>Mean duration of follow‐up ranged from 1.1 years for the <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a> trial to 10 years for the <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a> trial. The weighted average follow‐up was 4.1 years for the thiazide trials, 5.3 years for the beta‐blocker trials, 4.9 years for the ACE Inhibitor trials, and 2.5 years for the one calcium‐channel blocker trial. </p> </section> <section id="CD001841-sec-0068"> <h4 class="title">Excluded studies</h4> <p>We detailed the reasons for excluding 63 trials in the '<a href="./references#CD001841-sec-0114" title="">Characteristics of excluded studies</a>' table. </p> </section> </section> <section id="CD001841-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias for each included study using the Cochrane 'Risk of bias' tool for RCTs, described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001841-bbs2-0101" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from handbook.cochrane.org, 2011. ">Higgins 2011b</a>). Potential parameters of methodological quality listed in the 'Risk of bias' table include: method used to randomize participants, whether randomization was completed in an appropriate and blinded manner; whether participants, providers, outcome assessors, or a combination of these, were blinded to assigned therapy; whether the control group received a placebo or no treatment; percent of participants who did not complete follow‐up (dropouts); percent of participants not on assigned active or placebo therapy at study completion; selective reporting of outcomes; and other bias, in terms of funding of the trial by the manufacturer. </p> <p>Refer to <a href="#CD001841-fig-0002">Figure 2</a> for the 'Risk of bias' graph, which provides review authors' judgements about each risk of bias item, presented as percentages across all included studies. Refer to <a href="#CD001841-fig-0003">Figure 3</a> for the 'Risk of bias' summary, which provides review authors' judgements about each risk of bias item for each included study. </p> <div class="figure" id="CD001841-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001841-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001841-sec-0070"> <h4 class="title">Allocation</h4> <p>Randomization was at low risk of bias in 22 trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>). It was judged as unclear risk of bias in one trial (<a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>), and as high risk of bias in one trial (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>). </p> <p>Allocation concealment was at low risk of bias in 18 trials ((<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>), unclear risk of bias in five trials (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), and high risk of bias in one trial (<a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>). </p> </section> <section id="CD001841-sec-0071"> <h4 class="title">Blinding</h4> <p>Blinding of participant and personnel was at low risk of bias in 13 trials (<a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), as unclear risk of bias in three trials ( <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>), and high risk of bias in eight trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). </p> <p>Blinding of outcome assessor was at low risk of bias in 15 trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), unclear risk of bias in four trials (<a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>), and high risk of bias in five trials (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>) </p> </section> <section id="CD001841-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data was at low risk of bias in eight trials (<a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>), unclear risk of bias in seven trials (<a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>), and high risk of bias in nine trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>). </p> </section> <section id="CD001841-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Selective reporting was at low risk of bias in 13 trials (<a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>;<a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a> ), unclear risk of bias in five trials (<a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), and high risk of bias in six trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>). </p> </section> <section id="CD001841-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential bias was judged low risk in 13 trials (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>; <a href="./references#CD001841-bbs2-0023" title="Perry JrHM , et al. Evaluation of drug treatment in mild hypertension: VA‐NHLBI feasibility trial. Ann N Y Acad Sci1978;304:267‐288. [MEDLINE: 79040327] Perry JrHM , et al. Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res1977;40 suppl:1180‐187. [MEDLINE: 77160461] ">VA‐NHLBI 1978</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), unclear risk in 10 trials (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>), and high risk in one trial due to run‐in period leading to patient selection bias, plus funding bias (<a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>). </p> </section> </section> <section id="CD001841-sec-0075"> <h3 class="title" id="CD001841-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD001841-tbl-0001"><b>Summary of findings for the main comparison</b> First‐line low‐dose thiazide compared to placebo for hypertension</a>; <a href="./full#CD001841-tbl-0002"><b>Summary of findings 2</b> First‐line high‐dose thiazide compared to placebo for hypertension</a>; <a href="./full#CD001841-tbl-0003"><b>Summary of findings 3</b> First‐line beta‐blocker compared to placebo for hypertension</a>; <a href="./full#CD001841-tbl-0004"><b>Summary of findings 4</b> First‐line angiotensin converting enzyme inhibitor compared to placebo for hypertension</a>; <a href="./full#CD001841-tbl-0005"><b>Summary of findings 5</b> First‐line calcium channel blocker compared to placebo for hypertension</a> </p> <p>Refer to five Summary of findings tables: <a href="./full#CD001841-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001841-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001841-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001841-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001841-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD001841-sec-0076"> <h4 class="title">Primary outcomes by drug class</h4> </section> <section id="CD001841-sec-0077"> <h4 class="title">Thiazides</h4> <p>Because of the large number of trials, and the high heterogeneity in the effect between low dose and high dose thiazides on coronary heart disease events, we presented data for the two subgroups only, and not overall results for all thiazides. </p> <section id="CD001841-sec-0078"> <h5 class="title">Low‐dose thiazides</h5> <p>First‐line low‐dose thiazide significantly reduced all the primary outcomes: mortality (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.82 to 0.97; N = 19874; RCTs = 8; I² = 0%; <a href="./references#CD001841-fig-0004" title="">Analysis 1.1</a>), stroke (RR 0.68, 95% CI 0.60 to 0.77; N = 19874; RCTs = 8; I² = 0%; <a href="./references#CD001841-fig-0005" title="">Analysis 1.2</a>), coronary heart disease (RR 0.72, 95% CI 0.61 to 0.84; N = 19,022; RCTs = 7; I² = 0%; <a href="./references#CD001841-fig-0006" title="">Analysis 1.3</a>), and total cardiovascular events (RR 0.70, 95% CI 0.64 to 0.76; N = 19,022; RCTs = 7; I² = 0%; <a href="./references#CD001841-fig-0007" title="">Analysis 1.4</a>). The <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> trial was the only one that reported total hospitalizations, an acceptable measure of total serious adverse events. It showed a numerical reduction with treatment (RR 0.95, 95% CI 0.89 to 1.01, N = 4736; RCT = 1; <a href="./references#CD001841-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD001841-sec-0079"> <h5 class="title">High‐dose thiazides</h5> <p>First‐line high‐dose thiazide, in contrast, significantly reduced stroke (RR 0.47, 95% CI 0.37 to 0.61; N = 19,839; RCTs = 11; I² = 46%; <a href="./references#CD001841-fig-0005" title="">Analysis 1.2</a>), and total cardiovascular events (RR 0.72, 95% CI 0.63 to 0.82; N = 19,839; RCTs = 11; I² = 35%; <a href="./references#CD001841-fig-0007" title="">Analysis 1.4</a>), but not mortality (RR 0.90, 95% CI 0.76 to 1.05; N = 19,839; RCTs = 11; I² = 21%; <a href="./references#CD001841-fig-0004" title="">Analysis 1.1</a>), or coronary heart disease (RR 1.01, 95% CI 0.85 to 1.20; N = 19,839; RCTs = 11; I² = 0%; <a href="./references#CD001841-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD001841-sec-0080"> <h5 class="title">Beta‐blockers</h5> <p>First‐line beta‐blockers reduced stroke (RR 0.83, 95% CI 0.72 to 0.97; N = 19313; RCTs = 5; I² = 7%; <a href="./references#CD001841-fig-0013" title="">Analysis 2.2</a>), and total cardiovascular events (RR 0.89, 95% CI 0.81 to 0.98; N = 19313; RCTs = 5; I² = 54%; <a href="./references#CD001841-fig-0015" title="">Analysis 2.4</a>), but not mortality (RR 0.96, 95% CI 0.86 to 1.07; N = 19313; RCTs = 5; I² = 25%; <a href="./references#CD001841-fig-0012" title="">Analysis 2.1</a>), or coronary heart disease (RR 0.90, 95% CI 0.78 to 1.03; N = 19313; RCTs = 5; I² = 4%; <a href="./references#CD001841-fig-0014" title="">Analysis 2.3</a>). </p> </section> <section id="CD001841-sec-0081"> <h5 class="title">Angiotensin converting enzyme (ACE) inhibitors</h5> <p>First‐line ACE inhibitors reduced mortality (RR 0.83, 95% CI 0.72 to 0.95; N = 6002; RCTs = 3; I² = 0%; <a href="./references#CD001841-fig-0019" title="">Analysis 3.1</a>), stroke (RR 0.65, 95% CI 0.52 to 0.82; N = 6002; RCTs = 3; I² = 0%; <a href="./references#CD001841-fig-0020" title="">Analysis 3.2</a>), coronary heart disease (RR 0.81, 95% CI 0.70 to 0.94; N = 5145; RCTs = 2; I² = 0%; <a href="./references#CD001841-fig-0021" title="">Analysis 3.3</a>), and total cardiovascular events (RR 0.76, 95% CI 0.67 to 0.85; N = 5145; RCTs = 2; I² = 0%; <a href="./references#CD001841-fig-0022" title="">Analysis 3.4</a>). </p> </section> <section id="CD001841-sec-0082"> <h5 class="title">Calcium channel blockers</h5> <p>First‐line calcium channel blockers reduced stroke (RR 0.58, 95% CI 0.41 to 0.84; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0026" title="">Analysis 4.2</a>), and total cardiovascular events (RR 0.71, 95% CI 0.57 to 0.87; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0028" title="">Analysis 4.4</a>), but not mortality (RR 0.86, 95% CI 0.68 to 1.09; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0025" title="">Analysis 4.1</a>), or coronary heart disease (RR 0.77, 95% CI 0.55 to 1.09; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0027" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD001841-sec-0083"> <h4 class="title">Secondary outcomes</h4> <section id="CD001841-sec-0084"> <h5 class="title">Reduction in systolic and diastolic blood pressure</h5> <p>Antihypertensive drug therapy significantly lowered both systolic and diastolic blood pressure, compared to the control group. Please refer to <a href="#CD001841-tbl-0006">Table 1</a> for details. </p> <div class="table" id="CD001841-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure lowering efficacy with different drug classes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fixed Effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Random Effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First‐line drug class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.56 (‐13.22 to ‐11.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.73 (‐5.12 to ‐4.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.10 (‐19.57 to ‐8.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.59 (‐8.41 to ‐2.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐13.66 (‐14.40 to ‐12.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.82 (‐7.24 to ‐6.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐23.29 (‐32.62 to ‐13.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.78 (‐16.20 to ‐9.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.51 (‐10.16 to ‐8.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.64 (‐6.06 to ‐5.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.20 (‐11.21 to ‐5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.85 (‐6.52 to ‐3.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐21.14 (‐23.13 to ‐19.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.64 (‐10.70 to ‐8.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐16.53 (‐35.72 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.59 (‐16.74 to 1.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.90 (‐10.14 to ‐7.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.50 (‐5.10 to ‐3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.90 (‐10.14 to ‐7.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.50 (‐5.10 to ‐3.90)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SBP: systolic blood pressure; DBP: diastolic blood pressure; MD: mean difference; CI: confidence interval </p> </div> </div> <p>First‐line low‐dose thiazides, compared to placebo or no treatment, decreased systolic blood pressure (mean difference (MD) ‐12.56, 99% CI ‐13.22 to ‐11.91; N = 18,685; RCTs = 8; I² = 98%; <a href="./references#CD001841-fig-0010" title="">Analysis 1.7</a>), and diastolic blood pressure (MD ‐4.73, 99% CI ‐5.12 to ‐4.34; N = 18,685; RCTs = 8; I² = 98%; <a href="./references#CD001841-fig-0011" title="">Analysis 1.8</a>). </p> <p>First‐line high‐dose thiazides, compared to placebo or no treatment, decreased systolic blood pressure (MD ‐13.66, 99% CI ‐14.40 to ‐12.91; N = 14,906; RCTs = 6; I² = 98%; <a href="./references#CD001841-fig-0010" title="">Analysis 1.7</a>), and diastolic blood pressure (MD ‐6.82, 99% CI ‐7.24 to ‐6.41; N = 19,347; RCTs = 10; I² = 97%; <a href="./references#CD001841-fig-0011" title="">Analysis 1.8</a>). </p> <p>First‐line beta‐blockers, compared to placebo or no treatment, reduced systolic blood pressure (MD ‐9.51, 99% CI ‐10.16 to ‐8.85; N = 18,833; RCTs = 5; I² = 92%; <a href="./references#CD001841-fig-0017" title="">Analysis 2.6</a>), and diastolic blood pressure (MD ‐5.64, 99% CI ‐6.06 to ‐5.22; N = 18,833; RCTs = 5; I² = 89%; <a href="./references#CD001841-fig-0018" title="">Analysis 2.7</a>). </p> <p>First‐line ACE Inhibitors, compared to placebo or no treatment, decreased systolic blood pressure (MD ‐21.14, 99% CI ‐23.13 to ‐19.15; N = 1071; RCTs = 2; I² = 98%; <a href="./references#CD001841-fig-0023" title="">Analysis 3.5</a>), and diastolic blood pressure (MD ‐9.64, 99% CI ‐10.70 to ‐8.58; N = 1071; RCTs = 2; I² = 98%; <a href="./references#CD001841-fig-0024" title="">Analysis 3.6</a>). </p> <p>First‐line calcium‐channel blockers, compared to placebo or no treatment, reduced systolic blood pressure (MD ‐8.90, 99% CI ‐10.14 to ‐7.66; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0030" title="">Analysis 4.6</a>), and diastolic blood pressure (MD ‐4.50, 99% CI ‐5.10 to ‐3.90; N = 4695; RCT = 1; <a href="./references#CD001841-fig-0031" title="">Analysis 4.7</a>). </p> <p>For each class of drugs, the blood pressure data were heterogeneous, however the effects remained highly significant, using the random‐effects model. Because of the high heterogeneity, and the fact that in many trials, other drugs were allowed, we did not think this was an accurate reflection of the blood pressure lowering effect of the first‐line drug. For the same reason, we did not present these data in the 'Summary of findings' tables, and no attempt was made to indirectly compare the different drugs for blood pressure. </p> </section> <section id="CD001841-sec-0085"> <h5 class="title">Withdrawal due to adverse effects</h5> <p>This outcome was not reported in most of the trials. Where it was reported, drug therapy increased withdrawals due to adverse effects, compared to placebo or no treatment: low‐dose thiazides (RR 2.38, 95% CI 2.06 to 2.75; N = 8870; RCTs = 3; I² = 96%; <a href="./references#CD001841-fig-0009" title="">Analysis 1.6</a>), high‐dose thiazides (RR 4.48, 95% CI 3.83 to 5.24; N = 15,170; RCTs = 7; I² = 31%; <a href="./references#CD001841-fig-0009" title="">Analysis 1.6</a>), and beta‐blockers (RR 4.59, 95% CI 4.11 to 5.13; N = 18,565; RCTs = 4; I² = 96%; <a href="./references#CD001841-fig-0016" title="">Analysis 2.5</a>). </p> <p>Because many of the trials did not report this outcome, and there was high heterogeneity between trials that did, we judged these data to have a high risk of bias. We could not calculate this information for the calcium channel blocker therapy, because withdrawals due to adverse drug effects were not reported in the <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a> trial, and authors declined to provide the information when requested. We could not use the data from the only ACE inhibitor trial that reported withdrawals due to adverse effects, as the untreated control group was not blinded (<a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001841-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001841-sec-0086"></div> <section id="CD001841-sec-0087"> <h3 class="title" id="CD001841-sec-0087">Summary of main results</h3> <p>This review, with a large amount of thiazide trial data (19 randomized controlled trials (RCTs), 39,713 participants), demonstrates the benefits of starting with a low‐dose thiazide as first‐line therapy for elevated blood pressure. The pooled data showed a reduction in total mortality when using a thiazide as the first‐line choice, and suggested that as first‐line therapy, low‐dose thiazide, reduced coronary heart disease events, whereas high‐dose thiazide did not. </p> <p>Five RCTs used a first‐line beta‐blocker (19,313 participants), and provided enough data to compare with first‐line thiazides. Analyses suggested that beta‐blockers reduced total stroke and total cardiovascular events less than all thiazides, and they reduced coronary heart disease less than a first‐line low‐dose thiazide. It is important to note that in four of the five beta‐blocker trials, atenolol was the beta‐blocker used. It is possible that the reduced effectiveness of first‐line beta blockers was limited to atenolol. </p> <p>First‐line angiotensin converting enzyme (ACE) inhibitors, in three RCTs and a smaller population (6002 participants), were associated with similar benefits, but wider confidence intervals than first‐line low‐dose thiazides for all outcomes. </p> <p>The amount of data for first‐line calcium channel blockers in one trial (4695 participants) was insufficient to make any meaningful comparisons; this can be appreciated by noting the wide confidence intervals associated with the treatment effects for this drug class (<a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>). </p> <p>Relative risk (risk ratio) is the best way to indirectly compare the effectiveness between different drug classes. When we compared risk ratios (RR), beta blockers (RR 0.89, 95% confidence interval (CI) 0.81 to 0.98) appeared to be less effective than low‐dose thiazides (RR 0.70, 95% CI 0.64 to 0.76) in reducing total cardiovascular events. First‐line ACE inhibitors (RR 0.76, 95% CI 0.67 to 0.85), and calcium channel blockers (RR 0.71, 95% CI 0.57 to 0.87), had less data, but could not be distinguished from low‐dose thiazides for the effect on total cardiovascular events, or other outcomes. </p> <p>However, for the patient, it is more meaningful to have a measure of the absolute risk reduction (ARR) over a specified period of time. We calculated this summary measure for total cardiovascular events for the four drug classes in three clinical settings, where it was possible: secondary prevention, primary prevention (moderate to severe hypertension), and primary prevention (mild to moderate hypertension). </p> <p><b>Secondary prevention</b>: For the three secondary prevention trials using thiazides, and the one secondary trial using an ACE inhibitor, the average baseline blood pressure was approximately 155/94 mmHg. The average total cardiovascular event rate was 23.1% over five years in the control group, and the RR with treatment was 0.76. Therefore, the ARR over five years was 5.5% (23.1 X 0.24). For the two secondary prevention beta‐blocker trials, there was no clear reduction in total cardiovascular events (RR 1.01, 95% CI 0.84 to 1.21). There were no secondary prevention trials that used calcium channel blockers. </p> <p><b>Primary prevention (moderate to severe hypertension)</b>: For the seven low‐dose thiazide trials in this category, the baseline systolic blood pressure was 175 mmHg, and the average total cardiovascular event rate over five years in the control groups was 16%. The RR with treatment was 0.68, for an ARR over five years of 5.1% (16 X 0.32). This is similar to the 5.5% calculated for secondary prevention. For the two beta‐blocker trials in this category, there was no significant reduction in total cardiovascular events (RR 0.88, 95% CI 0.71 to 1.02). In the one calcium channel blocker trial, the ARR over five years was 4.6% (16 X 0.29), and in the one ACE inhibitor trial, the estimated ARR over five years was 3.7% (16 X 0.23; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). </p> <p><b>Primary prevention (mild to moderate hypertension)</b>: There were five first‐line high‐dose thiazide trials in this category, with an average baseline systolic blood pressure of 160 mmHg. In these five trials, the average cardiovascular event rate in the control group over five years was 4.1%. The RR with first‐line high‐dose thiazide treatment was 0.80 (95% CI 0.69 to 0.94), and the ARR over five years was 0.82% (4.1 X 0.2). For the one beta‐blocker trial in this category, the RR with treatment was 0.82, and the ARR over five years was 0.74% (4.1 X 0.18). </p> <p>This demonstrates that the absolute benefits are at least as good for first‐line low dose thiazides as the other classes of antihypertensives. The number needed to treat for an additional beneficial outcome (NNTB) for a low‐dose thiazide in moderate to severe hypertension (average systolic 175 mmHg) is about 20 over a five‐year duration. The NNTB was only a little lower in a secondary prevention setting, though the baseline blood pressures (average systolic 155 mmHg) were also lower. </p> <p>Notably, the NNTB was much higher, about 120 over five years, for primary prevention patients with mild to moderate hypertension. The low absolute benefit in individuals with lower blood pressure at baseline reflected two differences: the lesser relative benefit of a RR of 0.8 versus a RR of 0.7, and the lower five‐year event rate in the control groups of 4%. One of the limitations of this analysis was that the first‐line drug used in this population was a high‐dose thiazide, which the evidence suggests is not as effective. It is possible that using a low‐dose thiazide in these trials would have improved the benefit to a RR of 0.7. However, even if that was true, the absolute benefit would still be small (ARR = 1.2%; NNTB 83 over five years). The low absolute benefit of antihypertensive therapy for mild to moderate elevations in blood pressure in primary prevention needs to be reflected by authors of hypertension guidelines. </p> <p>Many of the patients in these trials also had co‐morbidities, such as diabetes mellitus. In this review, it was not possible to assess these patients separately, but <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a> analyzed their diabetes subgroup, and found the relative benefit was the same, and the absolute benefit was greater in diabetic patients than in non‐diabetic patients. </p> </section> <section id="CD001841-sec-0088"> <h3 class="title" id="CD001841-sec-0088">Overall completeness and applicability of evidence</h3> <p>Since 72.7% of participants in this review were primary prevention, the data are primarily relevant to a primary prevention population. Three of the included first‐line thiazide trials included participants with a prior stroke or transient ischemic attack (TIA; (<a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0014" title="PATS collaborating group. Post‐stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal1995;108(9):710‐7. [MEDLINE: 96147646] ">PATS 1996</a>)). When we deselected these trials from the thiazide analyses, the treatment effect estimates did not change. When we deselected all trials in which the baseline prevalence of myocardial infarction was either not reported (<a href="./references#CD001841-bbs2-0002" title="BarracloughM , JoyMD , MacGregorGA , FoleyTH , LeeMR , RosendorffC , et al. Control of moderately raised blood pressure. Report of a co‐operative randomized controlled trial. British Medical Journal1973;III:434‐6. [MEDLINE: 73241176] ">Barraclough 1973</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>), or was greater than 10% (<a href="./references#CD001841-bbs2-0003" title="CarterA . Hypotensive therapy in stroke survivors. Lancet1970;I:485‐9. [MEDLINE: 70117169] ">Carter 1970</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>), the treatment effect for total cardiovascular events was not different. For first‐line ACE inhibitors, <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a> was predominantly secondary prevention, and the relative benefit with treatment was similar to the other two primary prevention trials (<a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). </p> <p>For sensitivity analyses, we deselected trials that were not placebo controlled and blinded, trials that were restricted to patients with isolated systolic hypertension, small trials, and trials using supplemental drugs from other defined classes. In all of these instances, there was no clinically important change in the treatment effect estimate. </p> <p>The data on withdrawals due to adverse effects were incomplete and heterogeneous. Therefore, it was difficult to compare the different drug classes for this outcome. However, there was nothing to suggest that other classes of drugs were better tolerated than first‐line low‐dose thiazides. </p> <p>The blood pressure data in this systematic review were heterogeneous. This was because the number of drugs used in the trials differed, and only 16 of the 24 trials were double‐blinded. Blood pressure measurements are subject to bias if the observer and the patient know what is being administered. Because of these factors, it was not possible to use the blood pressure data to assess the blood pressure lowering efficacy of the different classes of drugs, or to compare low‐dose and high‐dose first‐line thiazides. </p> <p>There is growing evidence that the surrogate marker ‐ the lowering of blood pressure ‐ is inadequate to predict health outcomes with antihypertensive therapy. Despite similar reductions in blood pressure, we found that first‐line low‐dose and high‐dose thiazide therapy had different impacts on the incidence of coronary heart disease. </p> <p>In the 15 of the 24 trials where it could be assessed, despite dose titration and the addition of supplemental drugs, about 40% of the patients did not achieve the target blood pressure. Four trials reported that 34% of the patients did not achieve the target systolic pressure of less than 160 mm Hg (<a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>; <a href="./references#CD001841-bbs2-0015" title="ApplegateWB , DavisBR , BlackHR , et al. Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society1991;39:1057‐64. [MEDLINE: 92091624] Bearden D. Allman R. McDonaldR , et al. Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society1994;42:1143‐49. [MEDLINE: 95052246] Black HR. Unger D. BurlandoA , et al. Part 6: Baseline physical examination findings. Hypertension1991;17(3 (Suppl II)):II‐77‐II‐101. [MEDLINE: 91153895] Borhani NO. Applegate WB. CutlerJA , et al. Part 1: rationale and design. Hypertension1991;17(3 (Suppl II)):II‐2‐II‐15. [MEDLINE: 91153891] Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine1997;16:681‐693. [MEDLINE: 97278485] Curb JD. Lee M. JensenJ , ApplegateW . Part 4: baseline medical history findings. Hypertension1991;17(3 (Suppl II)):II‐35‐II‐61. [MEDLINE: 91153893] Curb JD. Pressel SL. CutlerJA , et al. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA1996;276:1886‐92. [MEDLINE: 97122394] Davis BR. Wittes J. PresselS , et al. Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials1993;14:350‐361. [MEDLINE: 94038014] Franse LV. Pahor M. Di BariM , et al. serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension2000;18:1149‐54. [Accession number Current contents 343FE‐0021] Frost PH. Davis BR. BurlandoAJ , et al. Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation1996;94:2381‐88. [MEDLINE: 97080432] Hall WD. Davis BR. FrostP , et al. Part 7: Baseline laboratory characteristics. Hypertension1991;17(3 (Suppl II)):II‐102‐II‐122. [MEDLINE: 91153886] HawkinsCM . Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology1993;September/October:25‐27. [Accession number 1993303455] Kostis JB. Allen R. BerksonDM , et al. Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal1994;127:112‐21. [MEDLINE: 94099287] Kostis JB. Davis BR. CutlerJ , et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA1997;278(3):212‐216. [MEDLINE: 97361706] Kostis JB. Lacy CR. HallD , et al. The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology1994;74:464‐67. [MEDLINE: 94337726] Kostis JB. Prineas R. CurbJD , et al. Part 8: Electrocardiographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐123‐II‐151. [MEDLINE: 91153887] Menard J. Day M. ChatellierG , LaraghJH . Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension1992;5:325‐30. [MEDLINE: 92255887] Newman AB. TyrrellKS , KullerLH . Mortality over four years in SHEP participants with a low ankle‐arm index. Journal of American Geriatric Society1997;45:1472‐78. [MEDLINE: 98063204] Perry HM. Davis BR. PriceTR , et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA2000;284(4):465‐471. [Accession number Current contents 335QB‐0033] Petrovich H. Byington R. BaileyG , et al. Part 2: screening and recruitment. Hypertension1991;17 (Suppl II)(3):II‐17‐II‐23. [MEDLINE: 91153889] Probstfield JL. Applegate WB. BorhaniNO , et al. The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc. and Exper. Hyper.‐Theory and Practice1989;A11(5 &amp; 6):973‐89. [MEDLINE: 90003847] SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology1988;41(12):1197‐1208. [Accession number 1989036523] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club1991;115(3):65. [Accession number 1992021057] SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program. JAMA1991;265:3255‐3264. [MEDLINE: 91259640] Savage PJ. Pressel SL. CurbD , et al. Influence of long‐term, low‐dose, diuretic‐based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine1998;158:741‐751. [MEDLINE: 98213401] Vogt TM. Schron E. PresselS , et al. Part 3: Sociodemographic characteristics. Hypertension1991;17(3 (Suppl II)):II‐24‐II‐34. [MEDLINE: 91153892] Wassertheil S. Applegate WB. BergeK , et al. Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine1996;156:553‐561. [MEDLINE: 96178910] Wasserthell‐Smoller S. FannC. AllmanRM , et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine2000;160:494‐500. [MEDLINE: 20158236] Weiler PG. Camel GH. ChiappiniM , et al. Part 9: Behavorial characteristics. Hypertension1991;17(3 (Suppl II)):II‐152‐II‐161. [MEDLINE: 91153888] Wittes J. Davis B. BergeK , et al. Part 10: Analysis. Hypertension1991;17(3 (Suppl II)):II‐162‐II‐167. [MEDLINE: 91153890] ">SHEP 1991</a>; <a href="./references#CD001841-bbs2-0016" title="Black DM. Brand RJ. GreenlickM , et al. Compliance to treatment for hypertension in elderly patients: The SHEP pilot study. Journal of Gerontology1987;42(5):552‐57. [MEDLINE: 87309619] Furberg CD. Black DM. for the SHEP research group. The systolic hypertension in the elderly program: Methodological issues. European Heart Journal1988;9:223‐227. [MEDLINE: 88166820] Hulley SB. Feigal D. IrelandC , et al. Systolic hypertension in the elderly program (SHEP). Journal of the American Geriatric Society1986;34(2):101‐105. [MEDLINE: 86113041] Hulley SB. Furberg CD. Gurland B. McDonaldR , et al. Systolic Hypertension in the Elderly (SHEP): antihypertensive efficacy of chlorthalidone. The American Journal of cardiology1985;56(15):913‐20. [MEDLINE: 86073945] PerryHM , et al. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot study. Stroke1989;20:4‐13. [MEDLINE: 89101122] Perry Jr HM. McDonald RH. HulleySB , et al. Systolic hypertension in the elderly program, pilot study (SHEP‐PS): morbidity and mortality experience. Journal of Hypertension1986;4(Suppl 6):S21‐S23. [MEDLINE: 87282780] Vogt TM. Ireland CC. BlackD , et al. Recruitment of elderly volunteers for a multicenter clinical trial: The SHEP pilot study. Controlled Clinical Trials1986;7:118‐133. [MEDLINE: 86299645] Vogt TM. Ireland CC. GreenlickMR , HughesGH . Relation of life events to blood pressure control in the SHEP trial. American Journal of Preventive Medicine1988;4:1‐4. [MEDLINE: 88281234] ">SHEP‐P 1989</a>). In two trials, over 50% did not achieve the target systolic pressure of less than 150 mmHg (<a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>). The other nine trials reported that 40% of the patients did not achieve the target diastolic pressure of less than 90 mmHg (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>). This observation is extremely important clinically, as it means that physicians can only expect to achieve blood pressure targets in about 60% of the patients they treat. However, this does not mean that the patients who do not achieve the target will benefit less than those who do, as blood pressure reduction is only partly responsible for the risk reduction from antihypertensive treatment (<a href="./references#CD001841-bbs2-0089" title="BoisselJP , GueyffierF , BoutitieF , PocockS , FagardR . Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments.. Fund Clin Pharmacol2005;19:579‐584. ">Boissel 2005</a>). </p> <p>The evidence showed that starting with a low dose of thiazide, and only titrating up if necessary, significantly reduced the risk of coronary heart disease. In contrast, starting with a high dose (50 mg of hydrochlorothiazide or the equivalent) did not. Since the high‐dose therapy has no proven advantages, there is no justification for using high doses, or for comparing low‐dose and high‐dose thiazide therapies in a future trial. Therefore, the current recommendation for the use of thiazides in the management of hypertension is justifiable, based on the evidence presented here: start with a low dose (12.5 mg hydrochlorothiazide, or the equivalent), increase the dose if necessary, and do not exceed a dose of 50 mg of hydrochlorothiazide, or the equivalent. </p> <p>The fact that thiazides are similarly, or more effective than other drug classes in reducing mortality and morbidity, and that the evidence is most robust for thiazides, is reason by itself to prescribe them first for most patients with hypertension. The value of this approach is further supported by the fact that of the drug classes studied, the thiazides are the least expensive drug class in most countries. If more than one thiazide or thiazide‐like drug is available, then the least expensive one is the most rational choice. </p> <p>Additional information supporting the use of thiazides was recently published by <a href="./references#CD001841-bbs2-0117" title="PuttnamJ , DavisBR , PresselSL , WheltonPK , CushmanWC , LouisGT , MargolisKL , OparilS , WilliamsonJ , GhoshA , Einhorn PTand , BarzilayJI . Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults. Secondary analysis of a randomized clinical trial. JAMA Internal Medicine2017;177(1):67‐76. ">Puttnam 2017</a>. By using data from a national database, a post‐trial cohort surveillance study of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack trial (ALLHAT) examined whether the use of thiazide diuretics for the treatment of hypertension was associated with reduced risk of fracture, compared with non‐use. ALLHAT was a large randomized clinical trial that compared the effect of first‐step therapy with different classes of antihypertensive drug therapy (chlorthalidone, amlodipine, and lisinopril) in preventing fatal coronary heart disease (CHD), nonfatal myocardial infarction (primary outcome), or other cardiovascular disease (CVD) events. Hospitalized hip and pelvic fractures were chosen as endpoints, because they are almost always associated with hospitalization. A total of 22,180 participants, with a mean age of 70.4 years, were followed for up to eight years (mean 4.9 years) during masked therapy. Participants randomized to receive chlorthalidone versus amlodipine or lisinopril had a lower risk of fracture on adjusted analyses (hazards ratio (HR) 0.79, 95% CI 0.63 to 0.98; P = 0.04). The authors concluded that "findings from a large randomized clinical trial provide evidence of a beneficial effect of thiazide‐type diuretic therapy in reducing hip and pelvic fracture compared with treatment with other antihypertensive medications". </p> </section> <section id="CD001841-sec-0089"> <h3 class="title" id="CD001841-sec-0089">Quality of the evidence</h3> <p>We graded the overall quality of the evidence and developed 'Summary of findings' tables, using GRADEpro GDTsoftware (<a href="./references#CD001841-bbs2-0097" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). </p> <p>We created five 'Summary of findings' tables to display the quality of evidence and summary of the effects on clinically important outcomes, for first‐line low‐dose thiazides (<a href="./full#CD001841-tbl-0001">summary of findings Table for the main comparison</a>), high‐dose thiazides (<a href="./full#CD001841-tbl-0002">summary of findings Table 2</a>), beta‐blockers (<a href="./full#CD001841-tbl-0003">summary of findings Table 3</a>), ACE inhibitors (<a href="./full#CD001841-tbl-0004">summary of findings Table 4</a>), and calcium channel blockers (<a href="./full#CD001841-tbl-0005">summary of findings Table 5</a>). </p> <p>We found high‐quality evidence that first‐line low‐dose thiazides reduced mortality, stroke, CHD, and total cardiovascular events more than placebo. We found moderate‐quality evidence that high‐dose thiazides reduced stroke, and CVS events more than placebo, and low‐quality evidence that first‐line high‐dose thiazides did not reduce CHD more than placebo. </p> <p>We found low‐quality evidence that beta‐blockers reduced stroke, and total cardiovascular events more than placebo. </p> <p>We found moderate‐quality evidence that ACE inhibitors reduced mortality and total CVS events, and low‐quality evidence that they reduced stroke and CHD more than placebo. </p> <p>We found low‐quality evidence that calcium channel blockers reduced mortality, stroke, CHD, and CVS events more than placebo. </p> <p>We found low‐quality evidence that thiazides and beta‐blockers caused more participants to withdraw from the trials due to adverse effects than those who took placebo. </p> <p>We found low‐ to very low‐quality evidence that all four drug classes reduced systolic and diastolic blood pressure. </p> </section> <section id="CD001841-sec-0090"> <h3 class="title" id="CD001841-sec-0090">Potential biases in the review process</h3> <p>A potential limitation of attributing the benefit predominantly to the first‐line thiazide is the fact that in some of the thiazide trials, the first‐line therapy included the thiazide combined with another drug. In two trials, the first‐line therapy was a combination of a thiazide plus a potassium sparing diuretic (<a href="./references#CD001841-bbs2-0005" title="AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60 years. Fourth interim report of the European Working Party on High Blood Pressure in the Elderly. Clinical Science and Molecular Medicine1978;55:263s‐70s. [MEDLINE: 79084957] AmeryA , BerthauxP , BirkenhägerW , BoelA , BrixkoP , BulpittC , et al. Antihypertensive therapy in patients above age 60. Third interim report of the European Working Party on High Blood Pressure in the Elderly. Acta Cardiologica1978;33(2):113‐34. [MEDLINE: 78253259] AmeryA , BerthauxP , BirkenhägerW , BulpittC , ClementD , DeSchaepdryverA , et al. Antihypertensive therapy in elderly patients. Pilot trial of the European Working Party on High Blood Pressure in the Elderly. Gerontology1977;23(6):426‐37. [MEDLINE: 77247640] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High Blood Pressure in the Elderly. Postgraduate Medical Journal1986;62(732):919‐24. [MEDLINE: 87041226] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , DeruyttereM , et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet1985;1(8442):1349‐54. [MEDLINE: 85239319] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over age of 60. Lancet1986;2(8507):589‐92. [MEDLINE: 86309842] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub‐group analysis on entry stratification. Journal of Hypertension1986;4(6):S642‐7. [MEDLINE: 87282821] AmeryA , BirkenhägerW , BrixkoP , BulpittC , ClementD , deLeeuwP , et al. Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1985;3(Suppl 3):S501‐8. [MEDLINE: 93340848] AmeryA , DeSchaepdrijverA . European Working Party on High Blood Pressure in the Elderly (EWPHE): organization of a double‐blind multicenter trial on antihypertensive therapy in elderly patients. Clinical Science and Molecular Medicine1973;45(Suppl):71s‐3s. [MEDLINE: 74122575] AmeryA , DeSchaepdryverA . The European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):1S‐4S. [MEDLINE: 91174038] DeLeeuwPW . Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):45S‐9S. [MEDLINE: 91174047] European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Archives internationales de pharmacodynamie et de thérapie1985;275:300‐34. [MEDLINE: 85278499] European Working Party on High Blood Pressure in the Elderly (EWPHE). Antihypertensive therapy in the elderly. Ninth interim report. Netherlands Journal of Medicine1984;27:165‐70. [MEDLINE: 84246039] European Working Party on high blood pressure in the elderly trial. Discussion after the presentation of the results of the European Working Party on High Blood Pressure in the Elderly trial (EWPHE). Journal of Hypertension1985;3(Suppl 3):S509‐11. [MEDLINE: 93340848] FagardR . Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):62S‐3S. [MEDLINE: 91174052] FagardR , StaessenJ , AmeryA . Experience with diuretics in the study conducted by the European Working Party on High Blood Pressure in the Elderly (EWPHE). Progress in Pharmacology and Clinical Pharmacology1992;9:463‐72. [Accession number 1992230803] FletcherA , AmeryA , BirkenhägerW , BulpittC , ClementD , deLeeuwP , et al. Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1991;9:225‐30. [MEDLINE: 91237059] FletcherAE . Adverse treatment effects in the trial of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):42S‐4S. [MEDLINE: 91174046] O'MalleyK , CoxJP , O'BrienE . Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension. Cardiovascular Drugs and Therapy.1990;4:1249‐52. [MEDLINE: 91182687] O'MalleyKO , McCormackP , O'BrienET . Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. Journal of Hypertension1988;6(suppl 1):S105‐8. [MEDLINE: 89110528] PrisantLM , CarrAA . Overview of the findings of the European Party on High Blood Pressure in the Elderly. Geriatric Medicine Today1990;9(5):35‐8. [Accession number 1990224411] StaeesenJ . The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):50S‐4S. [MEDLINE: 91174049] StaessenJ . Mortality and treatment of blood pressure in patients of the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):60S‐1S. [MEDLINE: 91174051] StaessenJ , BulpittC , ClementD , DeLeeuwP , FagardR , FletcherA , et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ1989;298:1552‐6. [MEDLINE: 89336052] ThijsL . Age‐related hypotensive effect of placebo and active treatment in patients older than 60 years. The American Journal of Medicine1991;90(Suppl 3A):24S‐6S. [MEDLINE: 91174043] TuomilehtoJ . Body mass index and prognosis in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly. The American Journal of Medicine1991;90(Suppl 3A):34S‐41S. [MEDLINE: 91174045] VanHoofR . Left ventricular hypertrophy in elderly hypertensive patients: a report from the European Working Party on High Blood Pressure in the Elderly trial. The American Journal of Medicine1991;90(Suppl 3A):55s‐59s. [MEDLINE: 91174050] VanHoofR , StaessenJ , FagardR , ThijsL , AmeryA . The effect of antihypertensive treatment on electrocardiogram voltages in the European Working Party on High Blood Pressure in the Elderly trial. Journal of Cardiovascular Pharmacology1991;17(Suppl 2):S101‐4. [MEDLINE: 91350737] ">EWPHE 1985</a>; <a href="./references#CD001841-bbs2-0011" title="MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal1992;304:405‐12. [MEDLINE: 92191042] ">MRC‐O 1992</a>). Deselecting these two trials had no impact on the treatment effect. In five trials, a reserpine derivative was combined with the thiazide as first‐line therapy (<a href="./references#CD001841-bbs2-0007" title="Hypertension‐Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA1974;229:409‐18. [MEDLINE: 74258300] ">HSCSG 1974</a>; <a href="./references#CD001841-bbs2-0020" title="SmithWM , BouchardRJ , BromerL , et al. Morbidity and mortality in mild essential hypertension. Circ Res1972;30/31(Suppl II):110‐20. SmithWM , JohnsonWP , BromerL . Intervention trial in mild hypertension,U.S. Public Health Service Hospitals Cooperative Study Group. Intervention trial in mild hypertension, U.S. Public Health Service Hospitals Cooperative Study Group. Miami, Symposia Specialists: In Epidemiology and Control of Hypertension, edited by OPaul, 1975:461‐83. US. public health service hospital cooperative study group (USPHSHCSG). Treatment of mild hypertension. Results of a ten‐year intervention trial. Circ Res1977;40(Suppl 1):98‐105. [MEDLINE: 7706320] ">USPHSHCSG 1977</a>; <a href="./references#CD001841-bbs2-0021" title="FreisED . Antihypertensive Therapy; Principles and Practice, an International Symposium. In: GrossF editor(s). Antihypertensive Therapy; Principles and Practice, an International Symposium. New York: Springer‐Verlag, 1966:345‐54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. A double‐blind control study of antihypertensive agents. III. Chlorothiazide alone and in combination with other agents: preliminary results. Arch Intern Med1962;110:230‐5. [No unique identifier] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA1967;202:1028‐1034. [MEDLINE: 68044150] ">VA‐I 1967</a>; <a href="./references#CD001841-bbs2-0022" title="Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA1970;213:1143‐1152. [MEDLINE: 70243223] ">VA‐II 1970</a>; <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>. When these five trials were deselected, the treatment effect did not change either. Therefore, the data for first‐line thiazides appear robust, and the benefits achieved are most likely attributable to the first‐line thiazide therapy. </p> </section> <section id="CD001841-sec-0091"> <h3 class="title" id="CD001841-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>It is important in this type of analysis not to include trials in which there is significant contamination by drugs from other drug classes of interest. In our opinion, <a href="./references#CD001841-bbs2-0115" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis.. JAMA1997;277:739‐745. [MEDLINE: 97195474] ">Psaty 1997</a> incorrectly included the trial by <a href="./references#CD001841-bbs2-0032" title="CoopeJ . Randomised trial of treatment of hypertension in elderly patients in primary care. Brit Med J1986;293:1145‐1151. [MEDLINE: 87027421] ">Coope 1986</a> and the <a href="./references#CD001841-bbs2-0079" title="DahlofB , et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet1991;338:1281‐1285. [MEDLINE: 92047970] ">STOP 1991</a> trial in their beta‐blocker group. In the trial by <a href="./references#CD001841-bbs2-0032" title="CoopeJ . Randomised trial of treatment of hypertension in elderly patients in primary care. Brit Med J1986;293:1145‐1151. [MEDLINE: 87027421] ">Coope 1986</a>, 67% of patients in the active treatment group received bendrofluazide, and 70% received atenolol; in the <a href="./references#CD001841-bbs2-0079" title="DahlofB , et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet1991;338:1281‐1285. [MEDLINE: 92047970] ">STOP 1991</a> trial, more than 70% in the active treatment group received thiazides and more than 70% received beta‐blockers. Therefore, in those two trials, the treatment effect could not be attributed to first‐line thiazides or first‐line beta‐blockers. Other minor differences in the trials in this review and that by <a href="./references#CD001841-bbs2-0115" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis.. JAMA1997;277:739‐745. [MEDLINE: 97195474] ">Psaty 1997</a> are as follows. We classified <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a> as a low‐dose trial, and they classified it as high‐dose trial. It fit into our low‐dose category, based on the starting dose of 1 mg of trichlormethiazide. Moving the trial from the low‐dose to the high‐dose group did not change our findings. Unlike <a href="./references#CD001841-bbs2-0115" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis.. JAMA1997;277:739‐745. [MEDLINE: 97195474] ">Psaty 1997</a>, we excluded the Hypertension Detection and Follow‐up Program trial because it did not have an untreated control group, and the intervention group was treated with life‐style therapies in addition to drug therapy (<a href="./references#CD001841-bbs2-0041" title="HDFP . Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5‐year findings of the hypertension detection and follow‐up program. Hypertension1984;6(Suppl 1):198‐206. [MEDLINE: 84211011] ">HDFP 1984</a>). We included one small trial by <a href="./references#CD001841-bbs2-0024" title="WolffFW , LindemanRD . Effects of treatment in hypertension. Results of a controlled study. J Chron Dis1966;19:227‐240. [MEDLINE: 66114121] ">Wolff 1966</a>, not referenced by <a href="./references#CD001841-bbs2-0115" title="PsatyBM , SmithNL , SiscovickDS , KoepsellTD , et al. Health outcomes associated with antihypertensive therapies used as first‐line agents. A systematic review and meta‐analysis.. JAMA1997;277:739‐745. [MEDLINE: 97195474] ">Psaty 1997</a>. This trial was also included in the meta‐analysis in <a href="./references#CD001841-bbs2-0092" title="Collins , R , Peto , R , Macmahon , S , Hebert , P , Fiebach , N.H , Eberlein , k.A , Godwin , J , Qizilbash , N , Taylor , J.O , Hennekens , C.H . Blood pressure, stroke, and coronary heart disease‐ Part 2. Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335:827‐38. [MEDLINE: 90205389] ">Collins 1990</a> and in <a href="./references#CD001841-bbs2-0098" title="Gueyffier F. FromentA , GoutonM . New meta‐analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Human Hyperten1996;10:1‐8. [MEDLINE: 96219361] ">Gueyffier 1996</a>, The meta‐analysis by the blood pressure trialists group was incomplete and misleading because of their decision to exclude all trials prior to 1995 (<a href="./references#CD001841-bbs2-0088" title="TurnbullF , NealB , AlbertC , ChalmersJ , ChapmanN , CutlerJ , WoodwardM , MacMahon S: Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.. Arch Intern Med2005;165(12):1410‐1419. [MEDLINE: 15983291] ">BBLTTC 2005</a>). </p> <p>The network meta‐analysis included most of the trials comparing treatment versus placebo or no treatment that were included in this review (<a href="./references#CD001841-bbs2-0116" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , WeissNS . Health outcomes associated with various antihypertensive therapies used as first‐line agents: A network meta‐analysis. JAMA2003;289:2534‐2544. ">Psaty 2003</a>). However, they again incorrectly included two trials in their beta‐blocker group (<a href="./references#CD001841-bbs2-0032" title="CoopeJ . Randomised trial of treatment of hypertension in elderly patients in primary care. Brit Med J1986;293:1145‐1151. [MEDLINE: 87027421] ">Coope 1986</a>; <a href="./references#CD001841-bbs2-0079" title="DahlofB , et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOPHypertension). Lancet1991;338:1281‐1285. [MEDLINE: 92047970] ">STOP 1991</a>), and in our opinion, inappropriately included <a href="./references#CD001841-bbs2-0066" title="PROGRESS Collaborative Group. Randomised trial of a perindopril‐based blood‐pressure‐lowering regimen among 6105 individuals with previous stroke or transient ischemic attack.. Lancet2001;358:1033‐41. ">PROGRESS 2001</a>, <a href="./references#CD001841-bbs2-0045" title="ParvingHH , LehnertH , Brochner‐MortensenJ , GomisR , AndersenS , ArnerP . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. NEJM2001;345:870‐878. ">IDM 2001</a>, and <a href="./references#CD001841-bbs2-0054" title="LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , RitzE , AtkinsRC , RohdeR , RazI . Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to Type 2 Diabetes. NEJM2001;345:851‐860. ">Lewis 2001</a> as evidence for first‐line treatment in hypertension, when most patients did not have hypertension. Most importantly, this review includes four trials not included in the <a href="./references#CD001841-bbs2-0116" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , WeissNS . Health outcomes associated with various antihypertensive therapies used as first‐line agents: A network meta‐analysis. JAMA2003;289:2534‐2544. ">Psaty 2003</a> review (<a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>; <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a>; <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>). </p> <p>Our reasons for classifying <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> in this review deserve mention. First, in <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a>, the treatment target for the control group was over 200/105 mmHg for the first five years, after which it was lowered to over 180/105 mmHg. This was similar to the escape therapy in other trials that classified the control group as no treatment. For example, in the <a href="./references#CD001841-bbs2-0013" title="HelgelandA . Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. American Journal of Medicine1980;69:725‐32. [MEDLINE: 81059618] HelgelandA , BaksaasIA , LerenP . Mild hypertension ‐ early drug treatment or follow‐up only? the Oslo study. Acta Medica Scandinavica. Supplementum1979;626:34‐6. [MEDLINE: 79162188] HelgelandA , HjermannI , HolmeI , LirenP . Serum triglycerides and serum uric acid in untreated and thiazide‐treated patients with mild hypertension. American Journal of Medicine1978;64:34‐8. [MEDLINE: 78100666] HelgelandA , LerenP . Oslo study: treatment of mild hypertension. A five‐year controlled drug study. Nephron1987;47(Suppl 1):108‐10. [MEDLINE: 88097923] HelgelandA , LerenP , FossOP , HjermannI , HolmeI , Lund‐LarsenPG . Serum glucose levels during long‐term observation of treated and untreated men with mild hypertension. American Journal of Medicine1984;76:802‐5. [MEDLINE: 84200200] HolmeI . Coronary risk factors and their possible causal role in the development of coronary heart disease: the Oslo study. Journal of the Oslo City Hospitals1982;32(7‐8):80‐105. [MEDLINE: 83009420] HolmeI1 , HelgelandA , HjermannI , LerenP , MogensenSB . Correlates of blood pressure change in middle‐aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. The Oslo Study. American Journal of Epidemiology1988;127(4):742‐52. [MEDLINE: 88180946] LerenP , EideI , FossOP , HelgelandA , HjermannI , HolmeI , et al. Blood lipids and antihypertensive drugs. The Oslo study. Journal de pharmacologie (Paris)1983;14(Suppl II):217‐20. [MEDLINE: 84038026] LerenP , HegelandA , HjermannI , HolmeI . The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal1983;106:1200‐6. [MEDLINE: 84049074] LerenP , HelgelandA . Coronary heart disease and treatment of hypertension. Some Oslo Study data. American Journal of Medicine1986;80(Suppl 2A):3‐6. [MEDLINE: 86127395] LerenP , HelgelandA . Oslo hypertension study. Drugs1986;31(Suppl 1):41‐5. [MEDLINE: 86247179] ">OSLO 1986</a> trial, drug treatment in the control group was started if blood pressure exceeded 179/109 mmHg and was sustained. Second, the <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> target in the intervention group (less than 150/85 mmHg) was very similar to the targets in the intervention groups of the included studies in this review (less than 140 to 160/less than 80 to 90 mmHg). Third, the difference in blood pressure achieved between the treatment and control group over the nine years of the trial (10 to 11/4 to 6 mmHg) is similar to the difference in BP for other included trials in this review (9 to 12/3 to 6 mmHg; (<a href="./references#CD001841-bbs2-0001" title="AbernethyJD . The Australian therapeutic trial in mild hypertension. Hypertension1984;6(5):774‐6. [MEDLINE: 85053395] AbernethyJD . The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA1986;256(22):3134‐7. [MEDLINE: 87061296] DoyleAE . Cardiovascular morbidity and mortality in mild hypertension: the Australian trial. Journal of Cardiovascular Pharmacology1985;7(Suppl 2):S10‐3. [MEDLINE: 85238920] DoyleAE . The Australian therapeutic trial in mild hypertension. Nephron1987;47(Suppl 1):115‐9. [MEDLINE: 88094925] Management Committee. Initial results of the Australian therapeutic trial in mild hypertension. Report by the Management Committee. Clinical Science1979;57:449s‐52s. [MEDLINE: 80155869] Management Committee. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1980;1:1261‐7. [MEDLINE: 80208716] Management Committee. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet1982;1(8265):185‐91. [MEDLINE: 82102830] National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation of Australia. Medical Journal of Australia1981;2:398‐402. [MEDLINE: 82103405] ParryCA . Australian therapeutic trial in mild hypertension. Lancet1980;2(8191):425. [MEDLINE: 80253462; Letter] ReaderR . Australian therapeutic trial in mild hypertension. Medical Journal of Australia1984;140(13):752‐4. [MEDLINE: 84218996] ">ATTMH 1980</a>; <a href="./references#CD001841-bbs2-0010" title="KuramotoK , MatsushitaS , KuwajimaI , MurakamiM . Prospective study on the treatment of mild hypertension in the aged. Japanese Heart Journal1981;22:75‐85. [MEDLINE: 81170913] ">Kuramoto 1981</a>; <a href="./references#CD001841-bbs2-0012" title="Medical Research Council Working Party. Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of hypertension: Medical Research Council Working Party. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on Mild to Moderate Hypertension. British Medical Journal1977;1(6074):1437‐40. [MEDLINE: 77182986] Medical Research Council Working Party on Mild Hypertension. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet1981;2(8246):539‐43. [MEDLINE: 82012365] Medical Research Council Working Party on Mild Hypertension. Comparison of the antihypertensive efficacy and adverse reactions of two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: sub studies of the Medical Research Council's trials of treatment of mild hypertension. Journal of Clinical Pharmacology1987;27(4):271‐7. [MEDLINE: 88059767] Medical Research Council Working Party on Mild Hypertension. Coronary heart disease in Medical Research Council trial of mild hypertension. British Heart Journal1988;59(3):364‐78. [MEDLINE: 88183834] Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed.)1986;293(6553):988‐92. [MEDLINE: 87027367] Medical Research Council Working Party on Mild Hypertension. MRC trial of treatment of mild hypertension: principal results. British Medical Journal1985;291(6488):97‐104. [MEDLINE: 85253760] Medical Research Council Working Party on Mild Hypertension. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. BMJ1988;296(6636):1565‐70. [MEDLINE: 88281942] MiallWE , BrennanPJ , MannAH . Medical Research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine1976;51:563s‐5s. [MEDLINE: 77161072] PeartS . Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine1987;10(6):616‐20. [MEDLINE: 88151302] ">MRC‐TMH 1985</a>; <a href="./references#CD001841-bbs2-0017" title="Amery A. Birkenhager W. BulpittCJ , et al. Syst‐Eur. A multicenter trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol and organization. Aging1991;3(3):287‐302. [MEDLINE: 92110413] Birkenhager WH. Staessen J. GasowskiJ , LeeuwPW . Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the systolic hypertension in Europe (Syst‐Eur) trial. Journal of Nephrology2000;13:232‐237. [Accession number 331TE‐ 0011] Gasowski J. Birkenhager WH. StaessenJ , deLeeuwPW . Benefit of antihypertensive treatment in diabetic patients enrolled in the systolic hypertension in Europe (Sys‐Eur) trial. Cardiovascular Drugs and Therapy2000;14:49‐53. [Accession number 281MJ‐ 0006] GirerdX , AmeryA , BirkenhagerW , BulpittC , CoxJ , DeLeeuwP . SYST‐EUR: a multicenter trial of treatment of systolic hypertension in aged subjects. An initial report (French). Archives des Maladies du Coeur et des Vaisseaux1992;85(8):1243‐7. SlovickD , StaessenJ , BertP , BulpittC , deCortP , FagardR , et al. Nitrendipine in older patients with isolated systolic hypertension: second progress report on the Syst‐Eur trial. J Hum Hypertens1993;7(4):411‐2. SlovickDI , AmeryA , BirkenhagerW , BulpittCJ , CoxJ , deLeeuwP , et al. Syst‐Eur multicenter trial on the treatment of isolated hypertension in the elderly: first interim report. J Hum Hypertens1993;7(2):201‐3. Staessen J. Dekempeneer L. FagardR , et al. Treatment of isolated systolic hypertension. Journal of Cardiovascular Pharmacology1991;18(Suppl 1):S34‐S40. [MEDLINE: 92139861] Staessen JA. Amery A. BirkenhagerW , et al. Syst‐Eur‐ a multicenter trial on treatment of isolated systolic hypertension in the elderly: first interim report. Journal of Cardiovascular Pharmacology1992;19:120‐125. [MEDLINE: 92278050] Staessen JA. Fagard R. Thijs L. Celis H. ArabidzeGG , et al. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757‐764. [MEDLINE: 97443133] Staessen JA. Fagard R. ThijsL , et al. Subgroup and per protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Archives of Internal medicine1998;158:1681‐1691. [MEDLINE: 98364833] ">SYST‐EUR 1997</a>)). </p> <p><a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a> also included <a href="./references#CD001841-bbs2-0019" title="UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J1998;317:713‐720. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J1998;317:703‐713. United Kingdom Prospective Diabetes Study Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia1991;34:877‐90. ">UKPDS 39 1998</a> in their beta‐blocker review, published in 2007. In contrast to <a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a>, we did not include <a href="./references#CD001841-bbs2-0050" title="The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta‐blocker, oxprenolol: The international prospective primary prevention study in hypertension (IPPPSH). J Hypertens1985;3:379‐392. [MEDLINE: 86009562] ">IPPPSH 1985</a> as representing first‐line beta blockers, as more than 65% of the patients also received a thiazide. We did include <a href="./references#CD001841-bbs2-0004" title="Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non‐disabling ischemic stroke. Stroke1993;24:543‐8. ">Dutch TIA 1993</a> and <a href="./references#CD001841-bbs2-0018" title="ErikssonS , OlofssonBO , WesleyPO , for the TEST study group. Atenolol for secondary prevention after stroke. Cerebrovasc Dis1995;5:21‐25. ">TEST 1995</a>, which <a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a> did not. Other reviews did not include <a href="./references#CD001841-bbs2-0006" title="The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of angiotensin‐converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology1996;12:127‐37. YusufS , SleightP , PogueJ , BoschJ , DaviesR , DagenaisG . Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Outcomes Study Investigators. New England Journal of Medicine2000;342(3):145‐53. [MEDLINE: 10639539] ">HOPE HYP 2000</a>, as the data separated for the hypertensive group had not been published. We are thankful to the authors of HOPE for providing these data. The <a href="./references#CD001841-bbs2-0009" title="BeckettNS , ConnorM , SadlerJD , FletcherAE , BulpittCJ . Orthostatic fall in blood pressure in the very elderly: results from the Hypertension in the Very Elderly trial (HYVET) ‐ pilot. Journal of Human Hypertension1999;13(12):839‐40. [MEDLINE: 20087110] BulpittCJ , BeckettNS , CookeJ , DumitrascuDL , Gil‐ExtremeraB , NachevC , et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. Journal of Hypertension2003;21:2409‐17. ">HYVET pilot 2003</a> trial and the <a href="./references#CD001841-bbs2-0008" title="BeckettNS , PetersR , FletcherAE , StaessenJA , LiuL , DumitrascuD , et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Egyptian Journal of Medicine2008;358(18):1887‐98. [MEDLINE: 18378519] BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of Human Hypertension1994;8(8):631‐2. BulpittCJ , FletcherAE , AmeryA , CoopeJ , EvansJG , LightowlersS , et al. The Hypertension in the Very Elderly Trial (HYVET): rationale, methodology and comparison with previous trials. Drugs &amp; Aging1994;5(3):171‐83. PetersR , BeckettN , ForetteF , TuomilehtoJ , ClarkeR , RitchieC , et al. HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET‐COG): a double‐blind, placebo controlled trial. Lancet2008;7(8):683‐9. ">HYVET 2008</a> trial are more recent trials included in our review. Despite these differences, the conclusions and interpretation of the findings in this review are concordant with <a href="./references#CD001841-bbs2-0116" title="PsatyBM , LumleyT , FurbergCD , SchellenbaumG , PahorM , AldermanMH , WeissNS . Health outcomes associated with various antihypertensive therapies used as first‐line agents: A network meta‐analysis. JAMA2003;289:2534‐2544. ">Psaty 2003</a>, who concluded that thiazides were the first‐line drug of choice, and <a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a>, who concluded that beta‐blockers were not an appropriate first‐line drug choice. Refer to <a href="#CD001841-tbl-0007">Table 2</a> for further details. </p> <div class="table" id="CD001841-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">First‐line beta‐blocker compared to placebo. Comparison of this review with Wysonge 2017</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Present review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No of included studies* (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (19,313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (23,613)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.86 to 1.07)</p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.88 to 1.11)</p> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.81 to 0.98)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.79 to 0.97)</p> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total stroke</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.72 to 0.97)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.66 to 0.96)</p> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total coronary heart disease (CHD)</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.78 to 1.03)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.81 to 1.07)</p> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse effects</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.59 (4.11 to 5.13)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.38 (0.82 to 13.95)</p> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The 2 systematic reviews differed in study inclusion criteria; total number of studies included and quality of evidence for CHD. </p> <p>RR: relative risk; CI: confidence interval</p> </div> </div> <p>The recent <a href="./references#CD001841-bbs2-0123" title="TavernyG , MimouniY , LeDigarcherA , ChevalierP , ThijsL , WrightJM , GueyffierF . Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. Cochrane Database of Systematic Reviews2016, Issue 3. [DOI: 10.1002/14651858.CD011745.pub2] ">Taverny 2016</a> review assessed the effects of antihypertensive pharmacotherapy on three separate cardiac outcomes ‐ sudden cardiac death, fatal myocardial infarction, and nonfatal myocardial infarction in hypertensive individuals. In our review, these three outcomes were combined as total CHD events. In <a href="./references#CD001841-bbs2-0123" title="TavernyG , MimouniY , LeDigarcherA , ChevalierP , ThijsL , WrightJM , GueyffierF . Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. Cochrane Database of Systematic Reviews2016, Issue 3. [DOI: 10.1002/14651858.CD011745.pub2] ">Taverny 2016</a>, based on 15 randomized placebo‐controlled trials, in 39,908 patients, for a mean duration of 4.2 years, moderate‐quality evidence showed that antihypertensive therapy did not reduce sudden cardiac death (RR 0.96, 95% CI 0.81 to 1.15), but did reduce both nonfatal myocardial infarction (RR 0.85, 95% CI 0.74 to 0.98), and fatal myocardial infarction (RR 0.75, 95% CI 0.62 to 0.90). However, they did not report results separately for specific first‐line antihypertensive drug classes. Withdrawals due to adverse effects were increased in the drug treatment group to 12.8%, compared with 6.2% in the no treatment group. A Cochrane review, Pharmacotherapy for mild hypertension, has been published and is being updated (<a href="./references#CD001841-bbs2-0093" title="DiaoD , WrightJM , CundiffDK , GueyffierF . Pharmacotherapy for mild hypertension. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD006742.pub2] ">Diao 2012</a>). A systematic review, Pharmacotherapy for hypertension in adults (18 to 59 years), has recently been published (<a href="./references#CD001841-bbs2-0111" title="MusiniVM , GueyffierF , PuilL , SalzwedelDM , WrightJM . Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database of Systematic Reviews2017, Issue 8. [DOI: 10.1002/14651858.CD008276.pub2] ">Musini 2017</a>). The Cochrane review, Pharmacotherapy for hypertension in the elderly (60 years or older), is being updated (<a href="./references#CD001841-bbs2-0110" title="MusiniVM , TejaniAM , BassettK , WrightJM . Pharmacotherapy of hypertension in the elderly. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD000028.pub2] ">Musini 2009</a>). </p> <p>Since more trials comparing drug therapy with a placebo or no treatment are unlikely to be forthcoming, future evidence of effectiveness of first‐line therapy will need to come from head‐to‐head comparisons. Two Cochrane reviews have compared first‐line calcium channel blockers (<a href="./references#CD001841-bbs2-0091" title="ChenN , ZhouM , YangM , GuoJ , ZhuC , YangJ , WangY , YangX , HeL . Calcium channel blocker versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD003654.pub4] ">Chen 2010</a>) and first‐line drugs inhibiting the renin angiotensin system (<a href="./references#CD001841-bbs2-0129" title="XueH , LuZ , TangWL , PangLW , WangGM , WongGWK , WrightJM . First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD008170.pub2] ">Xue 2015</a>) with first‐line thiazides. These reviews confirm the likely morbidity benefits of first‐line thiazides. We are also currently working on a meta‐analysis of head‐to‐head trials in a separate systematic review. That review will focus on head‐to‐head trials comparing first‐line thiazides with other classes of drugs (<a href="./references#CD001841-bbs2-0119" title="ReinhartM , MusiniVM , SalzwedelDM , DormuthC , WrightJM . First‐line diuretics versus other classes of antihypertensive drugs for hypertension. Cochrane Database of Systematic Reviews2011, Issue 6. [DOI: 10.1002/14651858.CD008161.pub2] ">Reinhart 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001841-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD001841-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001841-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001841-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 1 Total mortality." data-id="CD001841-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 2 Total stroke." data-id="CD001841-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 2 Total stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 3 Total coronary heart disease." data-id="CD001841-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 3 Total coronary heart disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 4 Total cardiovascular events." data-id="CD001841-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 4 Total cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 5 Total hospitalizations." data-id="CD001841-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 5 Total hospitalizations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 6 Withdrawal due to adverse effects." data-id="CD001841-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 6 Withdrawal due to adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 7 Systolic blood pressure." data-id="CD001841-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 7 Systolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 First‐line thiazide vs placebo, Outcome 8 Diastolic blood pressure." data-id="CD001841-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 First‐line thiazide vs placebo, Outcome 8 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 1 Total mortality." data-id="CD001841-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 2 Total stroke." data-id="CD001841-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 2 Total stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 3 Total coronary heart disease." data-id="CD001841-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 3 Total coronary heart disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 4 Total cardiovascular events." data-id="CD001841-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 4 Total cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 5 Withdrawal due to adverse effects." data-id="CD001841-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 5 Withdrawal due to adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 6 Systolic blood pressure." data-id="CD001841-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 6 Systolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 First‐line beta‐blocker vs placebo, Outcome 7 Diastolic blood pressure." data-id="CD001841-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 First‐line beta‐blocker vs placebo, Outcome 7 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 1 Total mortality." data-id="CD001841-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 2 Total stroke." data-id="CD001841-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 2 Total stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 3 Total coronary heart disease." data-id="CD001841-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 3 Total coronary heart disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 4 Total cardiovascular events." data-id="CD001841-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 4 Total cardiovascular events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 5 Systolic blood pressure." data-id="CD001841-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 5 Systolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 6 Diastolic blood pressure." data-id="CD001841-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 First‐line ACE inhibitor vs Placebo, Outcome 6 Diastolic blood pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 1 Total mortality." data-id="CD001841-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 1 Total mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 2 Total stroke." data-id="CD001841-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 2 Total stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 3 Total coronary heart disease." data-id="CD001841-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 3 Total coronary heart disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 4 Total cardiovascular event." data-id="CD001841-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 4 Total cardiovascular event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 5 Heart Failure." data-id="CD001841-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 5 Heart Failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 6 Systolic blood pressure." data-id="CD001841-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 6 Systolic blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001841-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/urn:x-wiley:14651858:media:CD001841:CD001841-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_t/tCD001841-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 7 Diastolic blood pressure." data-id="CD001841-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 First‐line calcium channel blocker vs Placebo, Outcome 7 Diastolic blood pressure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/media/CDSR/CD001841/image_n/nCD001841-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001841-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line low‐dose thiazide compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line low‐dose thiazide compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting: o</b> utpatients<br/> <b>Intervention:</b> First‐line low‐dose thiazide (mean duration 4.1 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative</b> </p> <p><b>effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of</b> </p> <p><b>participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Low dose</b> </p> <p><b>thiazide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (90 to 107) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.82 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,874<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.2%; NNTB = 83</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>42 per 1000<br/> (37 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.68<br/> (0.60 to 0.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,874<br/> (8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 2%; NNTB = 50</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total coronary heart disease</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72<br/> (0.61 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,022<br/> (7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 1.1%; NNTB = 91</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total cardiovascular events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (83 to 98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.64 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,022<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 3.9%; NNTB = 26</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/> (102 to 136) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.38<br/> (2.06 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8870<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 6.8%; NNTH = 15</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to risk of selective reporting bias; only 3 of the 8 studies reported withdrawal due to adverse effects </p> <p>2. Downgraded due to inconsistency; I² = 96%</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">First‐line low‐dose thiazide compared to placebo for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001841-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">First‐line high‐dose thiazide compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line high‐dose thiazide compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> First‐line high‐dose thiazide (mean duration 4.1 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative</b> </p> <p><b>effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the</b> </p> <p><b>evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with High dose</b> </p> <p><b>thiazide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.76 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (7 to 12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/> (0.37 to 0.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1%; NNTB = 100</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (23 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.85 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,839<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>51 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000<br/> (32 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72<br/> (0.63 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,839<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 1.4%; NNTB = 71</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse</b> </p> <p><b>effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>98 per 1000<br/> (84 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.48</p> <p>(3.83 to 5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,170<br/> ( 7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 7.6%; NNTH = 13</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Downgraded due to imprecision; wide confidence limits.</p> <p>2 Downgraded due to bias secondary to lack of blinding of investigators.</p> <p>3 Downgraded due to high risk of selective reporting bias as only 7 of the 11 trials report this outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">First‐line high‐dose thiazide compared to placebo for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001841-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">First‐line beta‐blocker compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line beta‐blocker compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> First‐line beta‐blocker (mean duration 5.3 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Beta‐</b> </p> <p><b>blocker</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000<br/> (54 to 67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.86 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (24 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 0.6% NNTB = 167</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (34 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.78 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,313<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>76 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 1000<br/> (62 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.89<br/> (0.81 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,313<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 0.8% NNTB = 125</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to adverse</b> </p> <p><b>effects</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (129 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.59<br/> (4.11 to 5.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,565<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARI = 11.3% NNTH = 9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome; <b>NNTH:</b> Number needed to treat for an additional harmful outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1 Downgraded due to imprecision; wide confidence limits</p> <p>2. Downgraded due to high risk of performance and detection bias.</p> <p>3. Downgraded due to inconsistency; I² &gt; 50%</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">First‐line beta‐blocker compared to placebo for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001841-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">First‐line angiotensin converting enzyme inhibitor compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line angiotensin converting enzyme (ACE) inhibitor compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> First‐line ACE inhibitor (mean duration 4.9 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ACE</b> </p> <p><b>inhibitors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (98 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.72 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.3%; NNTB = 43</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000<br/> (31 to 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65<br/> (0.52 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6002<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.1%; NNTB = 48</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (95 to 127) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.70 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5145<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 2.5%; NNTB = 40</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>201 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>153 per 1000<br/> (135 to 171) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.76<br/> (0.67 to 0.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5145<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 4.8%; NNTB = 21</p> <p>Mostly secondary prevention population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to high risk of attrition and other bias.</p> <p>2. Downgraded due to imprecision (wide confidence interval).</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">First‐line angiotensin converting enzyme inhibitor compared to placebo for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001841-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">First‐line calcium channel blocker compared to placebo for hypertension</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>First‐line calcium channel blocker (CCB) compared to placebo for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adult patients with primary hypertension<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> First‐line CCB (mean duration 2.5 years)<br/> <b>Comparison:</b> placebo or untreated </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with CCB</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/> (41 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (14 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/> (0.41 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR = 1.5% NNTB = 67</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total coronary heart disease (CHD)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (17 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77<br/> (0.55 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4695<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>81 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>57 per 1000<br/> (46 to 70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.71<br/> (0.57 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4695<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ARR = 2.4% NNTB = 42</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>RCT:</b> randomized controlled trial; <b>ARR:</b> Absolute risk reduction; <b>ARI:</b> Absolute risk increase; <b>NNTB:</b> Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to imprecision (wide confidence intervals).</p> <p>2. Downgraded by 1 more level as there was only 1 trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">First‐line calcium channel blocker compared to placebo for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001841-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure lowering efficacy with different drug classes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Fixed Effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Random Effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>First‐line drug class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> <p><b>MD (99% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.56 (‐13.22 to ‐11.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.73 (‐5.12 to ‐4.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.10 (‐19.57 to ‐8.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.59 (‐8.41 to ‐2.76)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐13.66 (‐14.40 to ‐12.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.82 (‐7.24 to ‐6.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐23.29 (‐32.62 to ‐13.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.78 (‐16.20 to ‐9.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta‐blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.51 (‐10.16 to ‐8.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.64 (‐6.06 to ‐5.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.20 (‐11.21 to ‐5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.85 (‐6.52 to ‐3.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐21.14 (‐23.13 to ‐19.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.64 (‐10.70 to ‐8.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐16.53 (‐35.72 to 2.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.59 (‐16.74 to 1.55)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcium channel blocker</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.90 (‐10.14 to ‐7.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.50 (‐5.10 to ‐3.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.90 (‐10.14 to ‐7.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.50 (‐5.10 to ‐3.90)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>SBP: systolic blood pressure; DBP: diastolic blood pressure; MD: mean difference; CI: confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Blood pressure lowering efficacy with different drug classes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001841-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">First‐line beta‐blocker compared to placebo. Comparison of this review with Wysonge 2017</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Present review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001841-bbs2-0128" title="Wiysonge , Charles S.Bradley , Hazel A.Volmink , Jimmy.Mayosi , Bongani M.Opie , LionelH . Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD002003.pub2] ">Wiysonge 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No of included studies* (participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (19,313)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (23,613)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.86 to 1.07)</p> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.88 to 1.11)</p> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total cardiovascular events</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.81 to 0.98)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.79 to 0.97)</p> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total stroke</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.72 to 0.97)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.66 to 0.96)</p> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total coronary heart disease (CHD)</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.78 to 1.03)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.81 to 1.07)</p> <p>Moderate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse effects</b> </p> <p>RR (95% CI)</p> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.59 (4.11 to 5.13)</p> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.38 (0.82 to 13.95)</p> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>The 2 systematic reviews differed in study inclusion criteria; total number of studies included and quality of evidence for CHD. </p> <p>RR: relative risk; CI: confidence interval</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">First‐line beta‐blocker compared to placebo. Comparison of this review with Wysonge 2017</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/full#CD001841-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001841-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">First‐line thiazide vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.37, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total coronary heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.64, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total hospitalizations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawal due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [2.90, 3.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [2.06, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [3.83, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.04 [‐13.53, ‐12.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.56 [‐13.22, ‐11.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.66 [‐14.40, ‐12.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.71 [‐5.99, ‐5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.73 [‐5.12, ‐4.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 High‐dose thiazide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.82 [‐7.24, ‐6.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">First‐line thiazide vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001841-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">First‐line beta‐blocker vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total coronary heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawal due to adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.59 [4.11, 5.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.51 [‐10.16, ‐8.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.64 [‐6.06, ‐5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">First‐line beta‐blocker vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001841-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">First‐line ACE inhibitor vs Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.52, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total coronary heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.14 [‐23.13, ‐19.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.64 [‐10.70, ‐8.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">First‐line ACE inhibitor vs Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001841-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">First‐line calcium channel blocker vs Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Total stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.41, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total coronary heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Heart Failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.9 [‐10.14, ‐7.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Diastolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.5 [‐5.10, ‐3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">First‐line calcium channel blocker vs Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001841.pub3/references#CD001841-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001841.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001841-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001841-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001841-note-0022">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001841-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001841-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001841-note-0007">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001841-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001841-note-0009">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD001841-note-0005">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD001841-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001841-note-0021">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001841-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001841-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001841\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001841\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001841\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001841\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001841\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001841.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001841.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001841.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001841.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001841.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715935672"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001841.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715935676"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001841.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d933c7a589368',t:'MTc0MDcxNTkzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 